




# Enfermedades Infecciosas y Microbiología Clínica

[www.elsevier.es/eimc](http://www.elsevier.es/eimc)



Consensus statement

## Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant *Enterobacteriaceae*. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology



Jesús Rodríguez-Baño<sup>a,b,\*</sup>, José Miguel Cisneros<sup>a,c</sup>, Nazaret Cobos-Trigueros<sup>d</sup>, Gema Fresco<sup>e</sup>, Carolina Navarro-San Francisco<sup>f</sup>, Carlota Gudiol<sup>g</sup>, Juan Pablo Horcajada<sup>h</sup>, Lorena López-Cerero<sup>a</sup>, José Antonio Martínez<sup>d</sup>, José Molina<sup>a</sup>, Milagro Montero<sup>h</sup>, José R. Paño-Pardo<sup>f</sup>, Alvaro Pascual<sup>a,i</sup>, Carmen Peña<sup>g</sup>, Vicente Pintado<sup>e</sup>, Pilar Retamar<sup>a</sup>, María Tomás<sup>j</sup>, Marcio Borges-Sa<sup>k</sup>, José Garnacho-Montero<sup>c,l</sup>, Germán Bou<sup>j</sup>, for the Study Group of Nosocomial Infections (GEIH) of the Spanish Society of Infectious Diseases, Infectious Diseases (SEIMC)

<sup>a</sup> Unidad Clínica Intercentros de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Seville, Spain

<sup>b</sup> Departamento de Medicina, Universidad de Sevilla, Seville, Spain

<sup>c</sup> Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain

<sup>d</sup> Servicio de Enfermedades Infecciosas, Hospital Clinic, Barcelona, Spain

<sup>e</sup> Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, Spain

<sup>f</sup> Unidad de Enfermedades Infecciosas, Hospital Universitario La Paz, Madrid, Spain

<sup>g</sup> Servicio de Enfermedades Infecciosas, Hospital Universitario de Bellvitge – ICO, Barcelona, Spain

<sup>h</sup> Servicio de Enfermedades Infecciosas, Hospital Universitario del Mar/Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain

<sup>i</sup> Departamento de Microbiología, Universidad de Sevilla, Seville, Spain

<sup>j</sup> Servicio de Microbiología, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

<sup>k</sup> Servicio de Medicina Intensiva, Hospital Son Llàtzer, Palma de Mallorca, Spain

<sup>l</sup> Unidad Clínica de Cuidados Críticos y Urgencias, Hospital Universitario Virgen del Rocío, Seville, Spain

### ARTICLE INFO

#### Keywords:

Guidelines

Multidrug-resistant *Enterobacteriaceae*

Carbapenemases

Extended-spectrum  $\beta$ -lactamase

Therapy

### ABSTRACT

The spread of multidrug-resistant *Enterobacteriaceae* related to the production of extended-spectrum  $\beta$ -lactamases and carbapenemases is a serious public health problem worldwide. Microbiological diagnosis and therapy of these infections are challenging and controversial.

Clinically relevant questions were selected and the literature was reviewed for each of them. The information from the selected articles was extracted and recommendations were provided and graded according to the strength of the recommendations and quality of the evidence. The document was opened to comments from the members of the Spanish Society of Infectious Diseases and Clinical Microbiology, which were considered for inclusion in the final version.

Evidence-based recommendations are provided for the use of microbiological techniques for the detection of extended-spectrum  $\beta$ -lactamases and carbapenemases in *Enterobacteriaceae*, and for antibiotic therapy for invasive/severe infections caused by these organisms. The absence of randomised controlled trials is noteworthy; thus, recommendations are mainly based on observational studies (that have important methodological limitations), pharmacokinetic and pharmacodynamics models, and data from animal studies. Additionally, areas for future research were identified.

© 2014 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

\* Corresponding author.

E-mail address: [jesusrb@us.es](mailto:jesusrb@us.es) (J. Rodríguez-Baño).

## Diagnóstico y tratamiento de las infecciones invasivas causadas por *Enterobacteriaceae* multirresistentes. Guía de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

### R E S U M E N

#### Palabras clave:

Guía  
*Enterobacteriaceae* multirresistentes  
 Carbapenemasas  
 $\beta$ -lactamasas de espectro extendido  
 Tratamiento

La diseminación de *Enterobacteriaceae* multirresistentes en relación con la producción de  $\beta$ -lactamasas de espectro extendido y carbapenemasas es un importante problema de salud pública en todo el mundo. Tanto el diagnóstico microbiológico como el tratamiento de estas infecciones son complicados y controvertidos.

Los autores seleccionaron preguntas clínicamente relevantes, realizándose una revisión de la literatura para cada una de ellas; se obtuvo información de los artículos seleccionados y se realizaron recomendaciones que se clasificaron de acuerdo con la fuerza de la recomendación y la calidad de la evidencia. El documento estuvo abierto para los comentarios de los socios de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, los cuales se consideraron para su inclusión en la versión final.

Se proporcionan recomendaciones basadas en la evidencia y carbapenemasas para el uso de técnicas microbiológicas para la detección de  $\beta$ -lactamasas de espectro extendido y carbapenemasas en *Enterobacteriaceae*, y para el tratamiento antimicrobiano de las infecciones graves o invasivas causadas por estos microorganismos. Es llamativa la ausencia de ensayos aleatorizados, por lo que las recomendaciones se basan principalmente en estudios observacionales que tienen importantes limitaciones metodológicas, modelos farmacocinéticos y farmacodinámicos, y datos de estudios en animales. Además, se identificaron áreas prioritarias para la investigación futura.

© 2014 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.  
 Todos los derechos reservados.

### Introduction

The dramatic worldwide increase in the rate of infections due to *Enterobacteriaceae* showing resistance to several first-line antimicrobial families in most countries over the last decade<sup>1,2</sup> is recognised as a public health crisis.<sup>3</sup> The very limited therapeutic options available for these organisms are a real challenge. While several initiatives are being developed to facilitate the discovery and development of new antimicrobial agents and even non-antibiotic strategies for fighting resistance due to multidrug-resistant (MDR) and extremely drug-resistant (XDR) organisms,<sup>3–6</sup> the most urgent question to answer is what is the best available treatment for patients suffering these infections. Infections due to MDR *Enterobacteriaceae* are associated with increased mortality compared with their susceptible counterparts, which is mainly related to the intrinsic difficulties of therapy of MDR isolates.<sup>7,8</sup> To the best of our knowledge, evidence-based guidelines with evidence-based recommendations on the treatment for infections caused by MDR and XDR *Enterobacteriaceae* have not been published.

The main objective of this guideline is to provide evidence-based recommendations for the microbiological diagnosis and treatment of invasive infections caused by MDR and XDR *Enterobacteriaceae*, and specifically those producing the most epidemiologically and clinically important mechanisms of resistance. Additionally, areas for future research are identified.

This guideline is intended to be useful for all clinical microbiologists, for clinicians in direct charge of patients with the infections covered, and for consultants such as infectious diseases specialists, clinical microbiologists, hospital epidemiologists, and pharmacists, as well as policy makers in the field of antibiotic stewardship and quality-of-care professionals. It is the intention of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) to review these guidelines in 2016 or before in case of substantial changes in evidence.

### Methodology

This guideline was committed by SEIMC to a multidisciplinary group of Spanish clinicians and clinical microbiologists expert in the field. The authors selected a number of clinical questions by

consensus based on their perceived clinical importance. Then a systematic review of the literature was performed in PubMed for each of them. The abstracts of the literature selected articles were read, and those referring to the questions were selected for full review. References from these articles were also considered.

Because some of these pathogens may cause mild, non-invasive infections such as cystitis, the guideline is focused on invasive infections as described below, whatever their source. The document only targets microbiological diagnosis and antimicrobial therapy; therefore, other aspects of management other than *Enterobacteriaceae* are not considered. Only adult patients with these infections are covered. For this guideline, invasive infections are defined as focal or generalised infections causing a systemic inflammatory response syndrome (sepsis), including bacteraemic infections, needing hospital admission and/or intravenous antibiotic therapy.

Some of the mechanisms of resistance affecting broad-spectrum antibiotics in *Enterobacteriaceae* may cause heterologous level of resistance to some of these drugs, including low-level resistance or diminished susceptibility. Current susceptibility breakpoints are based on the concept that, given the pharmacokinetic/pharmacodynamic (PK/PD) properties of an antibiotic and the dose at which it is administered, it is the minimum inhibitory concentration (MIC) what is relevant for therapeutic decisions rather than the underlying mechanism of resistance.<sup>9–11</sup> However, this is controversial; some authors consider that doubts about the precision of MIC determination, the potential different levels of expression of resistance genes in vivo, the inoculum effect, and further induction of resistance in bacteria when exposed to antimicrobial agents may need to be considered.<sup>12</sup> Both aspects (MIC and mechanism of resistance) will be considered in this guideline according to available evidence. Definitions for MDR and extensively drug-resistant (XDR) organisms have been recently published<sup>13</sup> and will be used here. Such definitions do not correlate with the presence of the most important mechanisms of resistance; however, all extended-spectrum  $\beta$ -lactamase (ESBL), AmpC or carbapenemase-producing *Enterobacteriaceae* are at least MDR according to those definitions.

The data from each article related to each questions addressed were extracted using structured forms. For each topic, the quality of evidence and the strength of recommendations were evaluated and

**Table 1**  
Strength of recommendations and quality of evidence, modified from IDSA.

Category/grade	Definition
<i>Strength of recommendation</i>	
A	Strong recommendation for or against use
B	Moderate recommendation for or against use
C	Weak evidence to support a recommendation
<i>Quality of evidence</i>	
I	Evidence from >1 properly randomised, controlled trial
II	Evidence from >1 well-designed clinical trial without randomisation; from cohort of case-controlled analytic studies (preferably from >1 centre); from multiple time-series; or from dramatic results from uncontrolled experiments.
III	Evidence from opinion of respected authorities, based on clinical experience, descriptive studies, or reports from expert committees

Source: Modified from Ref. 14.

decided by the authors according to the methodology previously used by the Infectious Diseases Society of America (Table 1).<sup>14</sup>

The document was available to all SEIMC members during 4 weeks for their comments and suggestions, which were considered by the authors to write the final version.

### Microbiological diagnosis

The document will focus on ESBL- and carbapenemase-producing *Enterobacteriaceae* because these were considered the most relevant resistance mechanisms from both clinical and epidemiological points of view. The terms used in the literature review are specified in Table 2. No universal phenotypic or genotypic method exists which precisely embrace all ESBLs or carbapenemase types. The selected method to use will depend on the sample (surveillance or clinical), local prevalence, microorganism, resistance phenotype and resources.

#### Which phenotypic methods should be used to detect ESBL?

Depending on the goal to achieve, screening or confirmatory, different tests can be used.

**Screening.** For surveillance samples, the use of chromogenic media, designed for rapid detection and identification of ESBL-producing *Enterobacteriaceae*, is probably the best option. Although there are ESBL comparison studies, Brilliance ESBL agar® (ThermoFisher, UK) and ChromID ESBL® (bioMérieux, France) seem to offer similar sensitivity and specificity for this purpose.<sup>15</sup> These media reduce the need for bacterial identification in comparison with non-chromogenic selective media. Their most important limitation is the lack of specificity due to growth of AmpC-overproducing organisms (11–44%), K1/OXY-overproducing *Klebsiella oxytoca* and OXA-30-producing *Escherichia coli*.<sup>15</sup> Other selective media such as MacConkey agar supplemented with ceftaxime or ceftazidime (1–2 mg/L) had been used.<sup>16</sup>

There is no agreement about the best antimicrobial indicator and cut-off values for screening of ESBL in Gram-negative isolates both from clinical and surveillance samples. Cefpodoxime offers higher sensitivity than ceftaxime, ceftriaxone or ceftazidime. Nevertheless, the use of ceftazidime along with ceftaxime (see MIC and zone diameter breakpoints on antimicrobial susceptibility following the European Committee on Antimicrobial Susceptibility Testing [EUCAST]<sup>9</sup> and Clinical Laboratory Standards Institute [CLSI] criteria<sup>10</sup>) or ceftriaxone is still recommended because of their higher specificity.<sup>17</sup>

**Table 2**  
Terms used in the literature searches.

Topic	Specific terms	Comments
Microbiological diagnosis	ESBL detection, carbapenemase detection, phenotypic tests, phenotypic methods, chromogenic, multiplex PCR, Real-time PCR, DNA microarrays, pyrosequencing, MALDI-TOF	Included only in searches on microbiological diagnosis
Microorganisms	<i>Enterobacteriaceae</i> , <i>Enterobacteria</i> , <i>Escherichia coli</i> , <i>Klebsiella</i> , <i>Proteus</i> , <i>Enterobacter</i> , <i>Serratia</i>	Included in all searches
Resistance	Antimicrobial resistance, multidrug resistance, multidrug resistant, extensively drug resistant, pan-resistant, extended-spectrum $\beta$ -lactamases, CTX-M, SHV, TEM, carbapenemases, <i>Klebsiella pneumoniae</i> carbapenemases, KPC, metallo- $\beta$ -lactamases, MBL, NDM, VIM, IMP, OXA	Included in all searches
Infection types	(No restrictions were applied)	Included searches about therapy
Therapy	Therapy, treatment, penicillins, carbapenems, monobactams, cephalosporins, $\beta$ -lactam inhibitors, quinolones, aminoglycosides, polymyxins, tigecyclin, fosfomicin, sulphonamides	These terms were used in searches for specific questions related to therapy. All specific antimicrobial agents were also included
Epidemiology	Risk factors, predictors, predisposing factors	These terms were used in searches for epidemiological questions

**Confirmation.** Phenotypic ESBL confirmation is evaluated by ESBL inhibition by clavulanic acid.<sup>17</sup> This has limitations since some isolates can contain other resistance mechanisms than can mimic an ESBL (SHV-1 or K1 overproduction), *Klebsiella pneumoniae*-carbapenemase [KPC] carbapenemase) or the presence of ESBL (porin loss or AmpC-co-producers).<sup>16</sup> Inhibition by clavulanic acid may be studied by a double-disk synergy test (DDST) or by the combined-DDST (CDDST), which uses disks containing cephalosporins and clavulanic acid.<sup>10</sup> The activity of cephalosporins with or without clavulanic acid can be also evaluated by microdilution (3-dilutions difference)<sup>10</sup>; many automatic or semiautomatic susceptibility methods offer this possibility. The chromogenic Cica-Beta-Test® (Kantanto Chemical, Japan) requires further evaluation for ESBL confirmation.<sup>18</sup> ESBL Etest® strips are less efficacious and more expensive than CDDST since MIC values of cephalosporins in some ESBL-producing isolates can be out of the range of the strip<sup>19</sup> or yield false positive results.<sup>19</sup> For ESBL confirmation, the best option is probably the use of CDDST with ceftaxime, ceftazidime, and cefepime. In AmpC co-producers the best method to identify ESBL is CDDST available in ceftaxime and ceftazidime disks containing 3-aminophenylboronic acid (APBA).<sup>16,20,21</sup> However, both methods require further evaluation.

*Which phenotypic methods should be used to detect carbapenemase enzymes?*

**Screening.** For surveillance samples the use of chromogenic media is also probably the best option. CHROMagar KPC® (Hylabs, Israel) detects bacteria only with high-level resistance to carbapenems, but has poor sensitivity with low level of carbapenem lactam (MBL) producers. OXA-48-β-lactamase (MBL) producers. CRE Brilliance® (ThermoFisher) detects KPC and MBL but not all OXA-48 producers. Recently, an in-house medium containing ertapenem, cloxacillin and zinc named SUPERCARBA® has been described; it seems to improve the sensitivity for all types of carbapenemases including OXA-48. ChromID OXA-48 medium (bioMérieux, France) is specific for detection of OXA-48 producers. Also, chromID CARBA SMART (bioMérieux) is a media bi-plate that combines of ChromID CARBA (to detect KPC and MBL) on one side and ChromID OXA-48 media on the other but probably need further evaluation.

Detection of carbapenemase production in isolates based only on MIC values has low sensitivity and specificity. According to EUCAST and CLSI guidelines carbapenemase detection is only recommended for epidemiological purposes, although many authors disagree with this recommendation because of the scanty clinical data on the efficacy of carbapenems against carbapenemase-producing isolates with low MIC values and the low intermethod reproducibility for carbapenem MIC determination. Detection of carbapenemase activity has been recommended on any enterobacteria yielding MIC >0.12 µg/ml or <25 mm for ertapenem and/or meropenem and/or >1 µg/ml or <23 mm for imipenem (imipenem should not be used for genera *Proteus* spp., *Providentia* spp., and *Morganella* spp.). If disks are used a zone diameter of <23 mm for imipenem and/or meropenem and/or <25 mm for ertapenem would suggest the presence of a carbapenemase. Ertapenem has low specificity because of high MIC in some ESBL and/or AmpC producers; specifically, ertapenem should not be used as a marker for carbapenemase in *Enterobacter* spp.

**Confirmation.** The clover leaf method or modified Hodge test (MHT) is still used in many laboratories and it has been the only method of detection so far recommended by the CLSI. The MHT is still used in many laboratories; it is time-consuming, offers a low sensitivity for some enzymes (OXA-48) and species as *Enterobacter* and it does not distinguish among different classes of carbapenemases. Several phenotypic methods based on the inhibitory capacity of several compounds may provide information with respect to the molecular class of the carbapenemase. For instance, boronic acid compounds have shown availability to inhibit not only class A carbapenemase but also class A carbapenemases; cloxacillin inhibition may help to differentiate class A carbapenemase (no inhibition for cloxacillin) with respect to other mechanisms that also confer carbapenem resistance such as AmpC production plus reduction in permeability. To differentiate between classes A and C enzymes, others inhibitors such as chelating agents including ethylene diamine tetra-acetic acid (EDTA), 2-mercaptopropionic acid (2-MPA) or dipicolinic acid (DPA) can be used for inhibition-based MBL detection by DDST (double-disk-synergy test) or CD (combined-disk) methods. Besides, 30 µg temocillin disk can be added to differentiate OXA-48 producers (zone diameter ≤10 mm). A new test based on in vitro hydrolysis of imipenem named Carba NP® has been described. Hydrolysis of imipenem is detected by colorimetric measurement of changes in pH value. This rapid method (<2 h) yielded high sensitivity and specificity for detection of carbapenemase production belonging to Ambler classes A, B and D. Although promising, further evaluation is still needed. Nevertheless, regardless to the phenotypic method used, genetic confirmation is usually required for accurate confirmation of carbapenemase production.

**Table 3**  
Multiplex PCR for detection of the ESBLs and carbapenemase genes.

Genes detection	Strains or samples	Year	Ref.
- Multiplex I (TEM, SHV and OXA-1-like) - Multiplex II (CTX-M group 1, group 2 and group 9). CTX-M group 8/25 - Multiplex III (AAC, FOX, MOX, DHA, CIT and EBC) - Multiplex IV (VEB, PER and GES) - Multiplex V (GES and OXA-48-like) - Multiplex VI (IMP, VIM and KPC)	<i>Proteus mirabilis</i> , <i>Citrobacter freundii</i> , <i>Enterobacter cloacae</i> , <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i>	2010	29
- CTX-M group I (-1, -3, -10 to -12, -15, -22, -23, -28, -29, and -30) - CTX-M group II (-2, -4 to -7, and -20) - CTX-M group III (-8) - CTX-M group IV (-9, -13, -14, -16 to -19, -21, and -27)	<i>E. coli</i> , <i>Klebsiella</i> spp. and <i>Proteus</i> spp.	2011	30
- CTX-M group 1, group 2, group 8–25/26, and group 9 - Multiplex I (IMP, VIM, SPM, SIM, GIM) - Multiplex II (KPC, NDM, OXA-48)	Faeces samples  <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Citrobacter freundii</i>	2012	31  32
- SME, IMI/NMC-A, KPC, and GES - TEM, SHV, and CTX-M - AmpC (CMY, DHA, FOX, MOX, ACC, MIR, ACT) - KPC, VIM, NDM, OXA genes	<i>Klebsiella pneumoniae</i>  <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>Enterobacter cloacae</i> , <i>Klebsiella oxytoca</i> , <i>Citrobacter freundii</i> , <i>Proteus mirabilis</i> , <i>Enterobacter aerogenes</i> , <i>Morganella morganii</i> , <i>Enterobacter asburiae</i> , <i>Proteus vulgaris</i> and <i>Providentia rettgeri</i>	2012	33
- CTX-M groups, SHV and TEM	<i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>Enterobacter cloacae</i> , <i>Klebsiella oxytoca</i> , <i>Citrobacter freundii</i> , <i>Proteus mirabilis</i> , <i>Enterobacter aerogenes</i> , <i>Morganella morganii</i> , <i>Enterobacter asburiae</i> , <i>Proteus vulgaris</i> and <i>Providentia rettgeri</i>	2013	34
- CTX-M groups, SHV and TEM	Urine, pus, blood, IV/central line tip, sputum and body fluids	2013	35

Other methods such as spectrophotometric measurement of carbapenem hydrolysis are considered to be the reference standard methods for detection of carbapenemase production although they should be performed in reference laboratories.

*Rapid tests to detect ESBL and carbapenemase enzymes in specific situations*

Rapid detection of *Enterobacteriaceae* expressing either ESBL and/or carbapenemase-type may be very important in specific situations, such as for infection control purposes or in life-threatening infections. We consider rapid test as those providing the results on the same day; using this criteria, the spectrum of tests fulfilling this requirement is reduced to molecular (or genotypic) methods and those based on proteomic methods.

**Molecular methods.** Several rapid molecular approaches can be used:

- (a) There are many published studies of the application of multiplex PCR for detection of ESBLs and/or carbapenemase genes in *Enterobacteriaceae*. With respect to MBL, a commercial multiplex PCR (Hyplex-MBL ID Multiplex PCR-ELISA®), which was proven reliable in detecting *bla<sub>VIM</sub>* genes in blood,

- urine, exudate, and sputum samples, is available.<sup>36</sup> Overall, these methods lack clinical validation with multicentre studies.
- (b) Real-time polymerase chain reaction (RT-PCR) for the detection of ESBLs and/or carbapenemases by SYBR Green is less common than using TaqMan probes. Brolund et al. developed a real-time SYBR Green PCR assay for rapid detection of acquired AmpC in *Enterobacteriaceae* strains.<sup>37</sup> RT-PCR with probes genes encoding SHV-type ESBL<sup>38</sup> and KPC carbapenemases<sup>39</sup> have been described. Five types of class A and D enzymes (including GES, IMI/NMC, KPC, OXA-48 and SME) were rapidly detected by real-time TaqMan PCR in clinical isolates.<sup>40</sup> More importantly, some studies evaluated real-time PCR with probes in clinical samples. Detection of *bla*<sub>CTX-M</sub> genes was studied in 810 urine samples and 36 ESBLs-producing *Enterobacteriaceae*, mostly *E. coli*, were found with this technique.<sup>41</sup> In rectal samples from enrichment broth, RT-PCR for detecting KPC carbapenemase genes was compared with two selective screening agar plates (CHRO-Magar or VACC plates). RT-PCR showing higher sensitivity than both cultures (97% vs 77%).<sup>42</sup> Detection of KPC carbapenemase gene by quantitative RT-PCR TaqMan was carried out in BACTEC blood culture bottles in another study.<sup>43</sup> The sensitivity, specificity, positive and negative predictive value of this quantitative RT-PCR assay compared to the results of culture were all 100%. Also, in an outbreak situation caused by organisms producing an OXA-48-like enzyme, a RT-PCR has been used in stools samples with promising results.<sup>44</sup> A duplex RT-PCR assay for *bla*<sub>KPC</sub> and *bla*<sub>NDM</sub> (D-PCR) performed directly on perianal and perirectal swabs and stool was compared to PCR after broth enrichment (BE-PCR) and two culture methods (HardyCHROM ESBL<sup>®</sup> agar and CDC screening). Overall, D-PCR showed excellent sensitivity when specimens with visibly stool underwent preparatory extraction.<sup>45</sup> Also, a non-commercial multiplex PCR (with a new TaqMan probe) has been designed to detect all different allelic variants of *bla*<sub>KPC</sub> from easily available clinical specimens in less than 2 h.<sup>46</sup> Finally, it is worth mentioning the commercial EasyQ KPC<sup>®</sup> test (bioMérieux, Marcy l'Étoile, France), a novel RT-PCR assay that has recently been developed for *bla*<sub>KPC</sub> detection which showed no false positives.<sup>47</sup>
- (c) DNA microarrays for detection of the CTX-M, TEM and SHV genes ESBLs in *Enterobacteriaceae* strains have been described showing a sensitivity of 95% and specificity of 100%, using molecular characterisation of ESBLs by PCR and sequencing as reference.<sup>48</sup> Several commercial microarrays have been studied in clinical isolates. Check-KPC ESBL<sup>®</sup> microarray (Checkpoints, Wageningen, the Netherlands), using sequencing as reference method, showed a sensitivity of 97%, a specificity of 98%, a positive predictive value of 99% and a negative predictive value of 92%.<sup>49</sup> Also, Check-MDR CT101<sup>®</sup> microarray (Checkpoints, Wageningen, the Netherlands) has been studied for detection of the ESBLs.<sup>50,51</sup> One of the most promising approaches is the Check-MDR CT102<sup>®</sup> microarray (Checkpoints, Wageningen, the Netherlands), aimed at identifying bacteria producing several  $\beta$ -lactamases such as ESBL (SHV, TEM, and CTX-M) and carbapenemases (KPC, OXA-48, VIM, IMP, and NDM-1); the test showed a sensitivity and specificity of 100% for most of the tested genes.<sup>52,53</sup> Currently, this technology has only been used for bacterial isolates rather than clinical samples. Recently Bush et al. reported the need to include the gene of SME serine carbapenemase in the detection systems of carbapenemases arrays, especially when carbapenem-resistant *Serratia marcescens* isolates are suspected.<sup>54</sup>
- (d) Pyrosequencing is a so far a promising tool based on real-time sequencing by synthesis approach that has been applied to the single-nucleotide polymorphism detection for TEM- and SHV-type ESBL identification in clinical strains.<sup>55</sup> Further work is still needed to implement it in clinical practice.

**Proteomic methods.** The matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF MS) is a potentially useful tool for the detection of antimicrobial resistance, especially  $\beta$ -lactamases in *Enterobacteriaceae* and non-fermenting rods, with a turnaround time of 2.5 h.<sup>56</sup> Carbapenemase activity was identified in all carbapenemase-positive isolates studied, showing neither false-positive nor false-negative results.<sup>57</sup> Moreover, MALDI-TOF MS was applied to detect ESBL-producing *Enterobacteriaceae* directly from positive blood culture bottle with promising results.<sup>58</sup>

## Therapy

*When should empirical treatment of MDR Enterobacteriaceae be considered?*

It is well known that initial inappropriate antimicrobial therapy of severe infections leads to an increased morbidity and mortality.<sup>59,60</sup> Adequate therapy of severe infections caused by ESBL, plasmid-mediated AmpC or carbapenemase-producing *Enterobacteriaceae* is challenging, as many of the main agents typically used for infections caused by susceptible microorganisms are inactive. This may lead to extensive use of broad spectrum antibiotics, which would contribute to selection of further resistance and may also expose patients to unnecessary toxicity. Thus, selection of patients who should receive empirical treatment covering MDR enterobacteria is important.

First, clinical scenarios in which *Enterobacteriaceae* are likely pathogens should be considered. Second, the risk of MDR is related to the epidemiological situation (e.g., local prevalence, including community and hospital factors). While genes codifying for ESBL are found in the community and hospitals, carbapenemases are still mainly found in hospitalised patients, although OXA-48 may be already disseminating in the community.<sup>61</sup> Long term care facilities are well known as reservoirs for ESBLs, but are recently also being recognised as potential reservoirs also for carbapenemase-producing *Enterobacteriaceae* (CPE).<sup>62,63</sup> The updated percentage of isolates showing resistance to fluoroquinolones, third-generation cephalosporins and aminoglycosides among invasive isolates of *E. coli* and *K. pneumoniae* in European countries can be accessed at the EARS-Net website ([www.earsnet.eu](http://www.earsnet.eu)); although helpful, it should be noted that these data include only bacteraemic episodes and merge community and hospital infections; also, for microorganisms which frequently cause outbreaks (such as *K. pneumoniae*), the data from one country may not be representative of the situation in a single hospital.

Individual risk factors have been investigated in case-control and cohort studies of patients with bloodstream infections (BSI) caused by MDR *Enterobacteriaceae*. Regarding ESBL-producers in community-onset infections, risk factors were previously reviewed<sup>64</sup>; several multicentre studies have been developed in Spain, including different populations<sup>65–67</sup>; finally, a multinational study was also reported.<sup>68</sup> Of note, in spite of heterogeneity in study designs, populations and analysis, the results are quite similar across studies. The most frequently found risk factors for ESBL producers are age, healthcare-associated infection, long-term care facility admission, recurrent or obstructive urinary tract infections (UTI), urinary catheter, and previous antibiotic use (specifically, fluoroquinolones and cephalosporins). Two studies developed predictive scores for ESBL-producers. One of them, performed in Italy, included a derivation and a validation group<sup>69</sup>; the other, performed in the US, was based on the previous study data.<sup>70</sup> Both were case-control studies, which is not the most appropriate design for developing predictive models. The variables selected and their

**Table 4**  
Predictive scores for infection due to ESBL-producers at hospital admission according to published studies.

	Score in Ref. 70	Score in Ref. 71
Recent use of $\beta$ -lactams or fluoroquinolones	2	3
Recent hospitalisation (3 months)	3	2
Transfer from another healthcare facility	3	4
Charlson index >3	2	–
Recent history of urinary catheter	2	5
Age $\geq$ 70 years	2	–
Immunosuppression	–	2

punctuations are shown in Table 4. Anyway, a score value  $\geq$ 3 in both studies showed high sensitivity ( $\geq$ 94% in both models) and negative predictive value but a poor specificity; our interpretation is that this cannot be used for all patients; our interpretation is that this with severe sepsis or septic shock. On the other hand, a score value  $\geq$ 8 showed a high specificity ( $\geq$ 95% in both models) and positive predictive value with lower sensitivity, suggesting that it would be useful for not severe patients. Of note, another study challenged the predictive utility of the Tumbarello model.<sup>71</sup> Additionally, it should also be considered that recent travel to areas in which the prevalence of these mechanisms of resistance is high is also a risk factor, such as western Asia and the Indian subcontinent.<sup>72</sup>

The risk of nosocomial infection caused by ESBL-producers varies greatly according to the local epidemiology, even to a ward level. On the basis of local epidemiology and according to studies performed in Spain, individual risk factors include previous duration of hospital stay, exposure to invasive procedures (mainly mechanical ventilation), previous antibiotics (mainly cephalosporins and fluoroquinolones) and previous colonisation with these microorganisms.<sup>73–77</sup> Predictive scores have not been developed. Risk factors for infections caused by *Enterobacteriaceae* producing AmpC have been less studied.<sup>78–81</sup> Overall, the risk factors are similar to those for ESBL-producers; previous use of antibiotics selecting for these organisms (mainly cephalosporins) is also important.

Regarding CPE, most studies investigating risk factors were performed in the context of individual hospital outbreaks; age, severity of illness, admission to intensive care unit (ICU), previous use of antibiotics (mainly carbapenems, fluoroquinolones, cephalosporins), and invasive procedures (endoscopy, length of venous catheter use) have been identified.<sup>82–90</sup>

#### *Are carbapenems the drugs of choice for the treatment of invasive infections caused by ESBL-producing Enterobacteriaceae?*

Carbapenems are not affected by ESBLs and therefore, unless another mechanism of resistance affecting these drugs is expressed, ESBL-producers are fully susceptible to carbapenems.<sup>1,64,91</sup> We did not find any randomised clinical trials comparing carbapenems with other drugs for the treatment of infections caused by ESBL-producing organisms. A meta-analysis including 21 observational studies published until January 2012 on BSI concluded that carbapenems were associated with lower mortality when compared with cephalosporins in both empirical and definitive therapies, and with lower mortality than fluoroquinolones in empirical therapy; the differences were not significant for  $\beta$ -lactam/ $\beta$ -lactam inhibitor combinations (BLBLI).<sup>92</sup> Specific analyses by source of infection or organism (*E. coli* or *Klebsiella*) could not be performed. It should be noticed that appropriate therapy was associated with reduced mortality, and that comparisons among antibiotics were not controlled by susceptibility.

We found three observational studies on BSI published after this meta-analysis in which carbapenems were observationally compared to other in vitro active drugs using multivariate analysis; in one of them, cefepime was dependently associated with increased mortality in comparison with carbapenems<sup>93</sup>; in another, patients with haemodialysis access-related bacteraemia also showed higher mortality when treated with flomoxef than with carbapenems<sup>94</sup>; and in the third one, the use of carbapenems was also associated with lower mortality compared with all other antibiotics.<sup>95</sup> Thus, the available data suggest that carbapenems should be considered as the drugs of choice for the treatment of severe infections caused by ESBL-producing *Enterobacteriaceae* including bacteraemic infections with the potential exception of BLBLI (discussed below), but data for specific types of infections, microorganisms or isolates showing susceptibility to other antibiotics are limited.

#### *Which carbapenem should be used for ESBL-producers?*

Among carbapenems, most studies evaluated imipenem or meropenem.<sup>64,91</sup> The available data are limited for doripenem; a recently study performed a post hoc analysis of 6 randomised clinical trials evaluating doripenem in infections caused by ESBL-producers (1 in complicated UTI [cUTI] in comparison with levofloxacin, 2 in complicated intraabdominal infections [cIAI] in comparison with meropenem and 2 in hospital-acquired pneumonia [HAP], one compared to piperacillin/tazobactam and the other in comparison with imipenem); overall, 20/30 (61.7%) of patients treated with doripenem had a favourable outcome at test of cure, similar to comparators (24/39, 61.5%).<sup>96</sup> The numbers were too low to make comparisons with specific drugs or for specific indications.

Ertapenem is an interesting alternative because it has no activity against *Pseudomonas aeruginosa* or *Acinetobacter baumannii* and thus may contribute to reduce the pressure posed by other carbapenems against these pathogens.<sup>97–100</sup> We found 4 observational studies in which ertapenem was compared to other carbapenems in the treatment of BSI due to ESBL-producing *E. coli* or *K. pneumoniae*<sup>95,101–103</sup>; in none of them ertapenem was found to be associated with increased risk of death, either as empirical or definitive therapy. In one of those studies, mortality was higher if ertapenem MIC was  $\geq$ 0.5 mg/L, suggesting that present CLSI breakpoints are appropriate.<sup>103</sup> Development of ertapenem resistance or failure during therapy of ESBL- or AmpC-producing *Enterobacteriaceae* has been reported anecdotally<sup>104–108</sup>; by reviewing these cases, development of ertapenem resistance seems to be related with borderline MICs and/or complex infections; whether increasing the dose of ertapenem would avoid this has not been studied in clinical trials. Ertapenem has also been used successfully in patients with ventilator-associated pneumonia (VAP)<sup>109</sup> and as outpatient-antimicrobial therapy for UTI caused by ESBL-producers.<sup>110</sup> Recommended dosing regimens are shown in Table 5.

#### *Are there alternatives to carbapenems for invasive infections due to ESBL-producers?*

In order to avoid the overuse of carbapenems, alternatives for the treatment of ESBL-producers are needed. Potential alternatives include BLBLI, temocillin, cephalosporins, fluoroquinolones, trimethoprim-sulphamethoxazole, aminoglycosides, tigecycline, fosfomicin, and colistin.

As previously reviewed, cephalosporins are associated with higher mortality than carbapenems.<sup>92</sup> However, most of the available data come from studies in which cephalosporins were not active according to current breakpoints.<sup>9,10</sup> These breakpoints are supported mainly by PK/PD data<sup>111</sup>; however, available clinical data evaluating the efficacy of “active” cephalosporins in invasive

**Table 5**

Dose regimens recommended for the most frequently used drugs in the treatment of multidrug-resistant and extensively drug-resistant *Enterobacteriaceae*.

Antimicrobial	Standard dose	Recommended dose in case of severe infection and borderline susceptibility <sup>a</sup>	Strength and quality of recommendation
Meropenem	1–2 g/8 h	2 g/8 h (EI)	BII
Imipenem	0.5 g/6 h–1 g/8 h	1 g/8 h	CIII
Doripenem	0.5 g/8 h	1 g/8 h <sup>b</sup>	CIII
Ertapenem	1 g/24 h	1 g/12 h <sup>b</sup>	CIII
Ceftazidime	1 g/8 h	2 g/8 h (EI)	CIII
Amoxicillin–clavulanic acid	1/0.2 g/8 h	1.2 g/6 h or 2.2 g/8 h	BIII
Piperacillin/tazobactam	4/0.5 g/8 h	4/0.05 g/8 h or 4/0.5 g/6 h in critically ill patients (EI)	BIII
Colistin	1–2 MU/8 h	LD: 6–9 MU MD: 4.5 MU/12 h	BIII
Amikacin <sup>c</sup>	15 mg/kg/day	20 mg/kg/day	CIII
Tigecycline	LD: 100 mg. MD: 50 mg/12 h	LD: 150–200 mg MD: 75–100 mg/12 h	BIII
Fosfomycin disodium	4–6 g/6 h or 8 g/8 h	Not defined	CIII

EI, extended infusion; LD, loading dose; MD, maintenance dose.

<sup>a</sup> Patients with normal renal function. Toxicity should be closely monitored in all cases.

<sup>b</sup> Scarce clinical experience with this dose.

<sup>c</sup> Monitoring peak and trough levels is recommended.

infections caused by ESBL-producers are still limited and sometimes contradictory.<sup>112–117</sup> As regards cefepime, higher mortality than carbapenem was observed considering CLSI breakpoints, but mortality was lower for isolates with MIC  $\leq 1$  mg/L than for isolates with higher MIC.<sup>117</sup> As regards cephamycins, which are typically active against ESBL producers if no other mechanism of resistance is present, there are scarce data. Two small observational studies evaluated flomoxef in comparison with carbapenems with contradictory results.<sup>118,94</sup> Also, a retrospective cohort study showed similar efficacy of cefmetazole and carbapenems in patients with pyelonephritis due to ESBL-producers (cure rate, 9/10 vs 12/12, respectively).<sup>119</sup>

Regarding BLBLI, a post hoc analysis of prospective cohorts of *E. coli* showed similar results for empirical or definitive therapy with in vitro active BLBLIs and carbapenems after controlling for confounders<sup>120</sup>; the sources of BSI in this study were mostly urinary and biliary tracts, and high doses were used (amoxicillin/clavulanic acid: 2/0.2 g/8 h; piperacillin/tazobactam, 4/0.5 g/6 h). The same group also assessed the importance of piperacillin-tazobactam MIC in the outcome of 39 episodes of BSI due to ESBL *E. coli*; all 11 patients with urinary tract infections survived, irrespective of the MIC. For other sources, 30-day mortality was lower for isolates with a MIC of  $\leq 2$  mg/L than for isolates with a higher MIC (0% vs 41.1%;  $P=0.02$ ).<sup>121</sup> As explained above, a recent meta-analysis of observational studies could not find that mortality was lower in patients who received empirical or definitive therapy with carbapenem in comparison with BLBLI.<sup>92</sup> Administration of piperacillin/tazobactam extended infusion (4/0.5 g every 8 h in 3–4 h) is associated with better PK/PD target achievement, and has been associated with improved outcomes.<sup>122</sup>

Temocillin, which is not commercialised in Spain, is stable against ESBLs and AmpC enzymes<sup>123</sup>; its efficacy did not seem to be

affected by ESBL or AmpC-production in an observational study,<sup>124</sup> but studies comparing temocillin with other drugs are lacking.

As stated above, empirical therapy with fluoroquinolones was associated with higher mortality than carbapenems.<sup>92</sup> However, this may be due to the fact that ESBL-producers are frequently resistant to fluoroquinolones. Tumbarello et al. described a high mortality rate (50%) in 8 episodes of BSI due to ESBL-producing *Enterobacteriaceae* who were treated with ciprofloxacin<sup>60</sup>; in all these patients, the ciprofloxacin MICs were in the limit of susceptibility or intermediate according to EUCAST (0.5–1 mg/L).<sup>9</sup> There is no reason to suspect a lower efficacy for the rate isolates with lower MICs.

Data on aminoglycosides, tigecycline, fosfomycin and colistin will be discussed in the specific sections addressing these drugs.

#### *Should combination therapy be used for invasive infections caused by CPE?*

Resistance to carbapenems in *Enterobacteriaceae* is most frequently caused by the production of carbapenemases, although resistance may arise as a consequence of combined production of other  $\beta$ -lactamases and reduced permeability, augmented efflux, and alterations in PBP.<sup>125,126</sup> Carbapenemases may confer low to high level resistance to carbapenems and resistance to all other commercially available  $\beta$ -lactams, with the exception of aztreonam in the case of metallo- $\beta$ -lactamases (MBL) and oxy-imino-cephalosporins in the case of OXA-48 (but OXA-48 producers frequently co-produce ESBLs).<sup>2,126</sup> Also, temocillin may retain partial activity against KPC-producers.<sup>127</sup> Beyond that, most carbapenemase-producers are also resistant to quinolones and trimethoprim-sulphamethoxazole. Thus, the more frequently active drugs usually are colistin, fosfomycin, tigecycline and some aminoglycosides, but prevalence of susceptibility to these drugs is heterogeneous depending on location, genetic environment of the carbapenemase, and species.<sup>2,126–141</sup> Most reports have revealed a high proportion of treatment failures among patients with invasive infections caused by CPE with reported mortality rates ranging from 18% to 72%.<sup>2,126,128–143</sup> Patients in published series were treated with different regimens of monotherapy and combined therapy with variable results, which may be influenced by other prognostic factors such as age, severity of underlying conditions, severity of infection, site of infection, and administration of inappropriate antimicrobial therapy. Thus, adequate control of confounders is essential.

After a literature search, we could not find randomised trials comparing combination therapy with monotherapy in infections caused by CPE. We found 4 observational cohort studies analysing the impact of combination therapy on outcome, and using multivariate analysis<sup>133–135,139</sup>; the data are summarised in Tables 6 and 7. All but one<sup>135</sup> were retrospective studies, and all included patients with BSI due to KPC-producing *K. pneumoniae* (one of them also included VIM-producers<sup>139</sup>). In three of them, combination therapy was associated with lower mortality in comparison with monotherapy. In the study by Tumbarello et al. all active antimicrobials were used at high daily doses (colistin 6–9 millions of international units [MU], tigecycline 100–200 mg, gentamycin 4–5 mg/kg), and meropenem was administered by extended infusion at a dose of 2 g every 8 h. Monotherapy was used more frequently in cases with a urinary tract source whereas combination therapy was more common in ICU patients and in patients with suboptimal/borderline tigecycline and colistin MICs.<sup>133</sup> The study by Qureshi et al. did not control for presentation with shock.<sup>134</sup> The study by Zarkotou et al. found lower mortality among patients who were treated with combination therapy in the univariate analysis, but the multivariate analysis showed that it was

**Table 6**  
Clinical response and/or survival rate among patients with invasive infections caused by carbapenemase-producing *Enterobacteriaceae* treated with different antibiotic regimens from different cohorts. Data are expressed as percentage (no. of patients who survived/no. of patients treated).

	Reference			
	Tumbarello et al. <sup>133</sup>	Qureshi et al. <sup>134</sup>	Zarkotou et al. <sup>135</sup>	Daikos et al. <sup>139</sup>
Monotherapy	54 (25/46)	58 (11/19)	53 (8/15)	55 (40/72)
Carbapenem	NR	50 (2/4)	0 (0/1)	42 (5/12)
Tigecycline	47 (9/19)	20 (1/5)	60 (3/5)	59 (16/27)
Colistin	50 (11/22)	43 (3/7)	43 (3/7)	45 (10/22)
Aminoglycoside	20 (1/5)	100 (1/1)	100 (2/2)	78 (7/9)
Combination therapy	34 (27/79)	13 (2/15)	100 (20/20)	73 (75/103)
Carbapenem + colistin	NR	80 (4/5)	100 (2/2)	57 (4/7)
Carbapenem + tigecycline	NR	100 (3/3)	100 (1/1)	50 (2/4)
Carbapenem + aminoglycoside	NR	NR	0 (0/1)	89 (8/9)
Colistin + tigecycline	69 (16/23)	100 (1/1)	100 (9/9)	76 (16/21)
Colistin + aminoglycoside	NR	NR	100 (2/2)	71 (12/17)
Tigecycline + aminoglycoside	50 (6/12)	100 (2/2)	100 (3/3)	55 (11/20)
Carbapenem + tigecycline + colistin or aminoglycoside	13 (3/24)	NR	NR	100 (11/11)

NR, not reported.

appropriate therapy which had a protective effect on infection-related mortality.<sup>135</sup> Finally, the study by Daikos et al. included the highest number of patients; polymicrobial BSI were included, although this variable was included in the multivariate analysis; combination therapy was associated with lower mortality, particularly among patients with septic shock and rapidly fatal underlying disease.<sup>139</sup>

Other previous publications reviewed data from previous studies on combination therapy, including case series. Hirsch and Tam reviewed 15 articles on infections caused by KPC-producing *Enterobacteriaceae*.<sup>140</sup> Among the 55 cases included in the review (most of them UTIs), they found high rates of clinical success in patients who had received combination regimens including a polymyxin, or monotherapy with aminoglycosides or tigecycline. Similar results were reported by Lee and Burgess, who reviewed 38 articles comprising 101 infections (most of them BSI and respiratory infections).<sup>141</sup> They also found higher rates of clinical success in patients who received combination regimens. Polymyxin and carbapenem monotherapy were associated with higher rates of treatment failures compared with polymyxin or carbapenem-based combination therapy. Overall treatment failures were not significantly different in the three most common antibiotic-class combinations: polymyxin plus carbapenem,

polymyxin plus tigecycline or polymyxin plus aminoglycoside. Akova et al. reviewed the data from 9 studies that included 234 patients, most of them BSI (132 due to MBL-producing *K. pneumoniae* and 102 due to KPC-producing *K. pneumoniae*).<sup>142</sup> The overall success rate of combination therapy was significantly higher than that of monotherapy. In addition, the carbapenem-containing regimens were significantly more effective than the non-carbapenem-containing regimens. Tzouveleakis et al. compiled 34 articles comprising 301 patients with infections (161 infected with KPC-producing *K. pneumoniae* and 140 infected with MBL-producing *K. pneumoniae*).<sup>2</sup> The vast majority of these patients had invasive infections such as BSI or pneumonia. They found that the lower failure rate was observed for patients who received combination therapies including a carbapenem, and that this regimen was superior to combined therapy not including a carbapenem and to monotherapy with tigecycline or colistin. Tigecycline and colistin monotherapy resulted in failure rates comparable to that observed for patients who received inappropriate therapy. Finally, a recent systematic evaluation of antimicrobial therapy of CPE infections showed a wide clinical heterogeneity of the clinical reports that precluded the statistical analysis of the available evidence.<sup>143</sup> Overall, the data included in these reviews have important limitations because many of the infections evaluated belong to case

**Table 7**  
Studies investigating the impact of combination therapy in patients with invasive infection due to carbapenemase-producing *Enterobacteriaceae*; only studies using multivariate analysis are included.

Study	Tumbarello et al. <sup>133</sup>	Qureshi et al. <sup>134</sup>	Zarkotou et al. <sup>135</sup>	Daikos et al. <sup>139</sup>
Design	Retrospective cohort (3 Italian hospitals)	Retrospective cohort (2 US hospitals)	Prospective cohort (1 Greek hospital)	Retrospective cohort (2 Greek hospitals)
Number of patients	125	41	58	205
Type of infection	Bacteraemia	Bacteraemia	Bacteraemia	Bacteraemia
Microorganism	<i>K. pneumoniae</i>	<i>K. pneumoniae</i>	<i>K. pneumoniae</i>	<i>K. pneumoniae</i>
Carbapenemases	KPC-2, KPC-3	KPC-2, KPC-3	KPC-2	KPC-2 (79%), VIM-1
Definition for combination therapy	At least 2 active drugs	At least 2 drugs active against Gram negatives	Not specified	At least 2 active drugs
Main outcome variable	30-day mortality	28-day mortality	Related mortality during admission	Mortality during admission
Polymicrobial BSI	Not specified	Not specified	Excluded	Included <sup>a</sup>
Multivariate analysis	Logistic regression	Logistic regression	Logistic regression	Cox regression
Adjusted association of combination therapy with mortality (95% CI)	OR = 0.11 (0.02–0.69) <sup>b</sup>	OR = 0.07 (0.009–0.71)	No significant association (data not provided)	HR = 0.48 (0.28–0.81) <sup>c</sup>
Other variables associated with mortality	Inadequate initial therapy APACHE III Septic shock	Not specified	Inappropriate treatment APACHE II Age	Fatal underlying disease Septic shock

<sup>a</sup> Included in multivariate analysis.

<sup>b</sup> Refers to combination therapy with meropenem, colistin and tigecycline.

<sup>c</sup> The article provides HR for monotherapy; the inverse was calculated for combination therapy.



reports or small series of cases, with high potential for publication bias, where precise definitions of outcome were not given. In addition, the impact of antibiotic therapy on the mortality has not been adjusted for confounding factors such as the underlying comorbidities, site and severity of infection, drug dosage, or use of inappropriate antimicrobial therapy.

Finally, it is important to remember that most of the clinical data published in the literature on therapy have been related to KPC-producing *K. pneumoniae*, while published analysis of the experience with infections due to other carbapenemase-producers such as MBL or OXA-48 is sparse. Also, experience with specific sources of BSI is very limited. For instance, whether monotherapy with an appropriate active agent can be used in cases of BSI with a urinary tract source has not been appropriately studied. Also, there are no reasons to support that results with an active aminoglycoside in UTI would be different than for non-carbapenemase-producing organisms.

The limitations of the evidence available supporting combination therapy were highlighted in a recent systematic review and meta-analysis including studies on carbapenem-resistant Gram negatives (therefore, not only studies on *Enterobacteriaceae* were included, but also on *P. aeruginosa* or *A. baumannii*).<sup>144</sup> In that study, specific combinations could not demonstrate superiority against colistin monotherapy; only when combined combinations were included together, combination therapy was superior to colistin monotherapy.

#### *When and how should carbapenems be used for infections by carbapenemase-producing Enterobacteriaceae?*

Because of the very limited options for the treatment of CPE, carbapenems are to be discussed as potential options. The MICs for carbapenemase-producing *K. pneumoniae* may vary within a broad range of values, from 0.12 to >256 mg/L, depending on both the geographical location and the type of carbapenemase produced.<sup>2,126,128,130–132,145–150</sup> Thus, although VIM enzymes have strong carbapenem-hydrolytic activity, some VIM-producing *K. pneumoniae* isolates have low carbapenem MIC.<sup>146</sup> In contrast, the vast majority of isolates producing NDM show higher carbapenem MICs.<sup>147</sup>

Following the evaluation of MIC distributions of contemporary carbapenemase-producing isolates, PK/PD properties, and limited clinical outcome data, both EUCAST and CLSI recently revised their susceptibility breakpoints for carbapenems. EUCAST decided to set its clinical breakpoints for *Enterobacteriaceae* to  $\leq 2$  mg/L for imipenem, meropenem,  $\leq 1$  mg/L for doripenem, and  $\leq 0.5$  mg/L for ertapenem,<sup>9</sup> while CLSI reduced its previous breakpoint values to  $\leq 1$  mg/L for imipenem, meropenem, and doripenem, and to  $\leq 0.25$  mg/L for ertapenem.<sup>10</sup> The results should be reported as susceptible to carbapenems irrespective of the existence of mechanism of resistance. This is a controversial issue; some authors consider that there is a higher risk of failure with carbapenems in monotherapy<sup>148,149</sup> while lowering the breakpoints would allow the use of carbapenems in patients who may benefit from them.<sup>150</sup>

In the absence of randomised controlled trials, and because of the scarcity of clinical studies addressing this issue, we include a review of the literature for animal infection models and PK/PD studies.<sup>150–160</sup> In relation to animal infection models, the minimum proportion of time for which free carbapenem should remain above the MIC in a dosing interval ( $T > MIC$ ) was estimated to be 20–30% for bacteriostatic activity and 40–50% for bactericidal activity.<sup>151</sup> Most of the studies showed a significant effect against VIM-1-producing isolates with low imipenem MICs (2–4 mg/L) when imipenem was administered at high doses.<sup>150–153</sup> Bulik et al. showed that a high dose of meropenem (2 g every 8 h) infused

over 3 h was bactericidal against KPC-producing *K. pneumoniae* isolates with MICs of 2 mg/L.<sup>154</sup> However, although the targeted 40%  $T > MIC$  exposure was achieved by this dosing regimen against KPC-producing *K. pneumoniae* isolates with meropenem MICs up to 16 mg/L, this drug was not able to produce a reliable reduction in the bacterial density in 2 of the 3 isolates with MIC = 8 mg/L. In another study the efficacy of 1 and 2 g doses, and extended infusions of doripenem against KPC-producing *K. pneumoniae* isolates with MICs ranging 4–32 mg/L, in both immunocompetent and neutropenic mice, were evaluated.<sup>155</sup> The 1 g dose was able to produce only a bacteriostatic response with MICs of 4–8 mg/L, whereas the 2 g dose achieved a similar effect for isolates with MICs up to 16 mg/L. Compared to the neutropenic mice, a significant reduction in bacterial density was observed in immunocompetent animals, with overall decreases of up to 1 log with either the 1-g or the 2-g doripenem dose. A critical interpretation of the animal infection model data suggests that high-dosing, extended infusion regimens of carbapenems are able to achieve at least a bacteriostatic effect in severely compromised hosts and a modest bactericidal effect in immunocompetent animals infected with KPC-producing *K. pneumoniae* isolates with MICs up to 8 mg/L. Some recent data from animal models found that the type of carbapenemase may affect the activity of carbapenems, even for isolates with the same MIC. The results of these studies suggested that carbapenems would be less effective against KPC- and OXA-48- than against NDM-producers or against isolates with non-carbapenemase-related resistance to carbapenems.<sup>156–159</sup> Clinical experience with carbapenem monotherapy is limited to case reports, case series, retrospective studies and one prospective observational study. However, most studies have found that it is associated with a high rate of clinical failure and/or increased mortality.<sup>2</sup> A study compared the efficacy of carbapenemase-producing *K. pneumoniae* according to MIC<sup>149</sup>; it increased from 29% for a MIC of >8 mg/L to 60% for a MIC of 8 mg/L and to 69% for a MICs of  $\leq 4$  mg/L. Although the comparison between the groups was not statistically significant, it is worth noting that the efficacy of carbapenems in the last group was similar to that observed in 22 patients infected with non-carbapenemase-producing, carbapenem-susceptible *K. pneumoniae* (73%). Also, combination therapy including a carbapenem has been found to be associated with lower mortality than combinations without carbapenems in crude and adjusted observational comparisons when the carbapenem MIC was  $\leq 8$  mg/L, in the case of meropenem.<sup>133,139</sup> It should be remembered that meropenem was used at 2 g every 8 h, and administered by extended infusion in these studies. Of note, use of extended infusion of carbapenems may be associated with improved outcomes in critically ill patients.<sup>122</sup>

KPC enzymes show a high affinity for ertapenem; interestingly, the combination of ertapenem with doripenem showed enhanced activity in both in vitro and animal models, particularly for isolates with lower doripenem MIC.<sup>159–161</sup> Clinical experience is limited to a few successful anecdotal cases.<sup>162,163</sup>

#### *Which is the best combination for invasive infections caused by CPE?*

Again we did not find any randomised controlled trials to answer this question, and therefore the data from observational studies are analysed. In the retrospective cohort study by Tumbarello et al., 30-day survival was independently associated with the use of meropenem, colistin and tigecycline was optimised.<sup>133</sup> As previously stated, the doses for these antibiotics were optimised. Mortality rates were 0% (0/5) for meropenem MIC  $\leq 2$  mg/L, 20% (2/10) for MIC = 4 mg/L, 25% (1/4) for MIC = 8 mg/L, and 35.2% for MICs  $\geq 16$  mg/L. In the study by Qureshi et al., patients

who received colistin/polymyxin B or tigecycline monotherapy had significantly higher mortality (66.7%) than those treated with colistin/polymyxin B or tigecycline combined with a carbapenem (12.5%).<sup>134</sup> Also, Daikos et al. found a lower mortality in carbapenem-containing combinations than in carbapenem-sparing combinations (19.3% vs 30.6%), and also found that cases with a carbapenem MIC  $\leq 8$  mg/L had a lower mortality than those with a carbapenem MIC  $> 8$  mg/L (19.3% vs 35.5%).<sup>139</sup>

Additionally, some reviews summarised data from case series; it should be noted that these analyses are crude and no meta-analysis technique was used to analyse the data. Daikos et al. found that the combination of carbapenem with another active drug, such as an aminoglycoside, colistin or tigecycline, was associated with significant lower mortality than combinations of non-carbapenem drugs if the isolate had a carbapenem MIC of  $\leq 4$  mg/L<sup>150</sup>; Akova et al. found similar results.<sup>142</sup> Also, Tzouveleki et al. found patients receiving combinations therapy including a carbapenem had lower failure rate, and found a correlation between the response rate and carbapenem MICs among patients treated with carbapenem monotherapy, increasing from 25% (MIC  $> 8$  mg/L) to 66.7% (MIC = 8 mg/L), 71.4% (MIC = 4 mg/L), and 72.4% (MIC  $\leq 2$  mg/L).<sup>2</sup>

On the other hand, a recently published case series found a high rate of clinical response (92%) and low 30-day mortality (11.5%) among 26 polytrauma ICU patient treated with carbapenem-sparing combinations including tigecycline (100 mg every 12 h) in combination with gentamycin (19 patients) and/or colistin (12 patients, 4.5 millions IU every 12 h), and some of them also with fosfomicin (13 patients, 4 g every 8 h); 16 patients had VAP (5 of them bacteraemic).<sup>164</sup> The study does not include a control group treated with carbapenems in combination; it should be noticed that the mortality rate of VAP in this study is lower than expected.

#### When and how should colistin be used in the treatment of MDR *Enterobacteriaceae*?

The role of colistin in the treatment of *Enterobacteriaceae* infections has become increasingly relevant as the threat of carbapenem-resistant strains has spread, including some European countries.<sup>2,165</sup> The effectiveness of polymyxins in comparison to  $\beta$ -lactams has been questioned. Yahav et al. recently performed an analysis of pooled data from previously published studies, and observed a significant increase of mortality in the group treated with colistin compared to other antibiotics.<sup>166</sup> Although this effect could be explained to some extent by differences in the baseline features of patients with MDR organisms, the hypothesis of a reduced effectiveness of colistin was also supported by in vivo studies showing a poor tissue penetration<sup>167,168</sup> and by the previously scarce available information available on its PK/PD properties<sup>169</sup> which impaired the use of optimal dosing schedules. Moreover, since the exposure to colistin has been shown to be the main factor to induce the resistance to polymyxins,<sup>170,171</sup> it seems reasonable to preserve this last-resource antibiotic for infections with scarce available alternative options, such as those caused by CPE.

Because of the importance of early initiation of active treatment in severe CPE infections<sup>135</sup> colistin may be considered as part of the empirical regimen of patients with severe infections potentially caused by CPE, e.g. in the setting of a nosocomial outbreak or in patients with severe infections and risk factors in areas with a high prevalence of these organisms.

Colistin is usually available for endovenous administration as colistimethate (colistin methanesulfonate), a less-active prodrug which spontaneously hydrolyses to colistin (the active form).<sup>172</sup> There are two commercial presentations. Colomycin injection® (Xellia) is commercialised in vials containing 1 MU; 1 MU is equivalent to 80 mg of colistimethate. Coly-Mycin M Parenteral®

**Table 8**

Recommendations for colistin maintenance dosing for patients with impaired renal function not receiving renal replacement therapies (data are adapted from Ref. 183). This algorithm is not recommended for patients with creatinine clearance  $> 70$  ml/min, since calculated dose could be substantially higher than 300 mg of colistin base activity, whose safety has not been proved.

Daily maintenance dose of colistin (in mg of CBA)	Dosage interval (starting 24 h after the loading dose)
TPCC $\times (1.50 \times \text{CrCl} + 30)$	CrCl $< 10$ ml/min/1.73 m <sup>2</sup> : each 12 h CrCl 10–70 ml/min/1.73 m <sup>2</sup> : each 12 (or 8) h CrCl $> 70$ ml/min/1.73 m <sup>2</sup> : each 12 (or 8) h

CBA, colistin base activity (150 mg of CBA = 4.5 MU of colistin methanesulfonate); TPCC, targeted plasmatic concentration of colistin, according to MIC of the strain, the site and the severity of the infection; CrCl, creatinine clearance.

*Example:* For a patient with a CrCl of 40 ml/min/1.73 m<sup>2</sup> who needs colistin for treating a bloodstream infection produced by a *K. pneumoniae* strain with a colistin MIC = 1 mg/L, the minimum daily maintenance dose would be: 1 mg/L  $\times (1.50 \times 40 \text{ ml/min} + 30) = 90$  mg of CBA = 3 MU of colistin methanesulfonate. Thus, 24 h after the initial loading dose, a maintenance scheme of 1.5 MU each 12 h would be started.

(Parkdade Pharmaceuticals) is commercialised in vials with 150 mg of “colistin base” which is equivalent to 360 mg of colistimethate or 4.5 MU. Of note, dosing regimens recommended in the product labelling have been found to be too low in terms of PK/PD data, efficacy and selection of resistant strains.<sup>173,174</sup>

Recent well performed studies in critically ill patients provided new useful information about the PK/PD properties of colistin, which are being applied to dosing regimens. Colistin plasma concentrations are below the breakpoint (2 mg/L) for the first 48 h unless a loading dose is administered.<sup>173–175</sup> Therefore, administration of a 6–12 MU loading dose (or a body weight-based individualised dose) was suggested in critically ill patients.<sup>173</sup> Also, a longer half-life of colistin (up to 18 h) was shown in these studies, compared to the short half-life observed for colistimethate, and therefore, the suggested maintenance dose was 4.5 MU every 12 h.<sup>173–175</sup> However, caution is needed because the use of higher doses of colistin might increase the risk of nephrotoxicity.<sup>176–178</sup> Dal'fino et al. reported data on 28 infections caused by colistin-only susceptible Gram negative bacilli treated with a 9 MU loading dose of colistin followed by 4.5 MU each 12 h.<sup>179</sup> The clinical cure was high (82.1%), and the frequency of acute kidney injury was low (17.8%), all of which subsided rapidly. The study was uncontrolled, but it may be argued that these results improve the best favourable outcomes reported hitherto in similar ICU settings.<sup>180–183</sup> There is a lack of data for non-critical subjects, in whom the volume of distribution may be lower, and thus the risk of nephrotoxicity when using higher doses of colistin could be increased. Also, there are no available data for patients with extreme body weights.

As regards dosing in patients with renal impairment, the information is scarce and based on PK/PD studies that have not been validated in clinical studies hitherto. For patients not receiving renal replacement therapies we found only one recent population study that provided dosing recommendations according to creatinine clearance, based on a nomogram elaborated with the PK population analysis of 101 critically ill patients (Table 8).<sup>184</sup> Two studies including limited number of patients observed an efficient clearance of colistin in patients undergoing intermittent haemodialysis.<sup>174,184</sup> The results of both studies suggest the traditional dosing of 1 MU each 48 h is inappropriate, and recommend 1–2 MU each 12 h instead. A supplemental dose after the haemodialysis session (50% to the daily maintenance dose if administered during the last hour of dialysis, 30% if administered after the session) was recommended if the session cannot wait until the end of the dosing interval,<sup>174</sup> but no clinical studies have assessed these recommendations. Finally, a significant clearance of colistin has been observed in patients undergoing continuous

venovenous haemodiafiltration, but heterogenous results were obtained in different studies.<sup>174,185,186</sup> Probably, other factors (renal residual function, differences in the renal replacement mode, the haemofilter employed, etc.) are also important to explain these differences.

#### *When and how should fosfomycin be used in the treatment of invasive infections caused by MDR Enterobacteriaceae?*

Fosfomycin is an “old” antibiotic that inhibits the first step of peptidoglycan synthesis and shows potent bactericidal action against many Gram-negative and Gram-positive pathogens.<sup>187</sup> Fosfomycin tromethamine, an oral formulation, is approved in several countries for the treatment of cystitis. Also, fosfomycin disodium is also available for parenteral use in several countries. The drug shows little toxicity, achieves very high peak levels in serum and urine, and rapidly penetrates tissues.<sup>187</sup> Unfortunately, resistance may develop when used in monotherapy; available evidence suggest that emergence of resistance occurs more frequently with *P. aeruginosa* than with *E. coli* (the data for other *Enterobacteriaceae* are scarce), and less frequently in UTI than in other types of infection.<sup>188</sup>

In vitro studies showed that fosfomycin frequently retains good activity against several MDR *Enterobacteriaceae*, including ESBL and CPE.<sup>2,189–193</sup> Fosfomycin has also been shown to sometimes provide synergistic effect in combination with other antibiotics against different MDR *Enterobacteriaceae*; however, the grade of synergy depends on the strain and the accompanying antibiotics, and ranged from 55% to 79% with carbapenems, 7.1% to 36% with colistin, 21% to 30% with tigecycline, and 25% to 43% with gentamicin in one study.<sup>194</sup> However, this is not always the case: in another study which analysed 16 isolates of *non-KPC-producers*, only an additive effect with carbapenem was observed in isolates with low carbapenem MIC<sup>195</sup>; and combinations were not bactericidal against MBL-producers in another study.<sup>196</sup> Other potential benefit of using a combination regimen is the prevention of fosfomycin resistance development.<sup>197</sup>

In clinical practice, fosfomycin has been used in combination for the treatment of difficult-to-treat infections due to CPE.<sup>189,190</sup> Published data are reduced to small case series, and detailed information of all cases is not always specified. When analysing the data, it is necessary to consider the possibility of publication bias, that many patients who received fosfomycin in combination were seriously ill, and that fosfomycin may have been administered as a last resort, rescue therapy. Because of the scarcity of data, these series will be reviewed.

One study investigated a case series of 8 severely ill patients with invasive infections due to carbapenem-resistant *K. pneumoniae* who were treated with fosfomycin in combination with colistin, gentamicin or piperacillin-tazobactam; all-cause in-hospital mortality was 18.2%.<sup>198</sup> Secondary endpoints (such as clinical and microbiological outcomes, and the occurrence of any adverse effect) were favourable in all cases. In another study, fosfomycin was added after failure of initial therapy in 3 severely ill immunosuppressed patients with bacteraemia due to carbapenem-resistant *K. pneumoniae*; in all cases, bacteraemia relapsed after a short time period, in parallel with the development of antimicrobial resistance to fosfomycin and some of the other antibiotics.<sup>199</sup> Five patients within a series of 40 episodes of bacteraemia due to OXA-48-producing *K. pneumoniae* were treated with fosfomycin in combination with colistin (4 cases) and 3 primary BSI and 3 UTI or tigecycline (soft tissue infection); 2 patients died because of the infection.<sup>138</sup> Finally, a series of 48 patients with invasive infections caused by carbapenem-resistant *K. pneumoniae* or *P. aeruginosa* treated with fosfomycin in combination with colistin or tigecycline

were analysed.<sup>200</sup> The most frequent infections were primary bacteraemias and VAP. Mean fosfomycin daily dose was 24 g per day. 54.2% of patients were cured at day 14; mortality at day 30 was 37.5%. Nine of 15 patients with pandrug-resistant *K. pneumoniae* survived. Overall, 3 patients developed fosfomycin resistance.

As regards fosfomycin doses, 24 g per day (usually 6 g every 6 h or 8 g every 8 h) were administered in most of recent case series; a recent systematic review concluded that probably higher and more frequent doses may be needed in critically ill patients at least for the first 24–48 h, although there are no data to support any specific dosing scheme.<sup>201</sup>

#### *When and how should aminoglycosides be used in the treatment of invasive infections caused by MDR Enterobacteriaceae?*

Aminoglycosides are often one of the few antibiotics to which MDR and XDR *Enterobacteriaceae* are susceptible. However, the susceptibility rates are heterogeneous according to the specific microorganism and the local epidemiology.<sup>2</sup> In a meta-analysis and an evidence-based review for all types of pathogens and infections, monotherapy with aminoglycosides was found as efficacious as comparators ( $\beta$ -lactams and quinolones) for UTIs, although may be lower for other infections<sup>202,203</sup>; also, combinations of  $\beta$ -lactams and aminoglycosides did not seem to produce any benefit in comparison to monotherapy with a fully active  $\beta$ -lactam.<sup>204</sup> However, the situation may be different in case of MDR and XDR *Enterobacteriaceae*, in which the activity of first line drugs is seriously compromised.

Results of combinations in vivo studies have shown heterogeneous results. A synergistic effect was observed with the combination of fosfomycin and netilmicin against several carbapenemase-producing *K. pneumoniae*, ESBL-producing *K. pneumoniae* and ESBL-producing *E. coli* strains<sup>194</sup>; however, the combination of gentamicin and fosfomycin was indifferent against KPC-2 producing-*K. pneumoniae*.<sup>197</sup> Combinations of carbapenems and aminoglycosides have frequently shown in vitro synergy against some KPC-producing *K. pneumoniae* isolates,<sup>204,205</sup> which was also shown in an animal model.<sup>204</sup> In a endocarditis model of the infection caused by an ESBL-producing *K. pneumoniae* (TEM-3), the combination of piperacillin-tazobactam and gentamicin also showed a synergistic effect.<sup>206</sup> However, no synergistic effect has been observed in vitro in other studies with ESBL-producers.<sup>207,208</sup> To the best of our knowledge, studies with carbapenemases other than KPC are lacking.

In the clinical setting aminoglycosides have been used alone or in combination for the treatment of several infections caused by carbapenemase producers. During an outbreak due to KPC-2-producing *K. pneumoniae* in Greece involving 22 patients, 5 patients with pneumonia received aminoglycoside plus colistin (plus tigecycline in 2 patients) and all of them presented a favourable outcome; an additional patient with bacteraemia achieved clinical cure with gentamycin alone.<sup>209</sup> Daikos et al., in their cohort study of bacteraemic patients with KPC or VIM producing *K. pneumoniae*, found 8 patients treated in monotherapy with aminoglycosides, of which one died, and 57 treated in combinations, of which 28% died.<sup>139</sup> Zarkotou found no infection-related mortality in 2 patients treated in monotherapy with aminoglycosides and 8 treated in combination.<sup>135</sup> However, the types of the infection were not detailed in these reports. Navarro-San Francisco et al. found that, among patients with bacteraemia due to OXA-48-producing *K. pneumoniae*, 8 out of 12 patients received fosfomycin in combination with other antibiotics (6 with tigecycline, 3 with carbapenems, 2 with colistin and 1 with ciprofloxacin) died; on the other hand, 2 patients with catheter-related bacteraemia who received monotherapy with an aminoglycoside survived, whereas

a third patient with bacteraemia from the urinary tract died from other causes.<sup>138</sup> A case report described a patient with endocarditis due to KPC-3-producing *K. pneumoniae* who fully recovered after antibiotic treatment with gentamicin plus colistin, without the need of surgical intervention.<sup>210</sup> Finally, Alexander et al., in a series of UTI due to KPC-producing *K. pneumoniae*, found that all 7 patients receiving aminoglycoside therapy (gentamycin monotherapy in 5 of them) had successful clinical and microbiologic responses.<sup>211</sup>

The experience is also limited in infections due to ESBL-producing organisms. In a retrospective study involving 44 patients with bacteraemia due to ESBL-producing *K. pneumoniae*, 2 out of 4 patients who received an active aminoglycoside in monotherapy died.<sup>212</sup> Two more patients received aminoglycosides in monotherapy in a retrospective series of 35 episodes of bacteraemia caused by TEM-52-producing *K. pneumoniae* (the source was not specified); even though the isolates were not susceptible, both patients responded.<sup>213</sup> Gudiol et al. observed that aminoglycosides plus BLBLI showed similar mortality rates than carbapenems as empiric therapy of BSI due to ESBL-producing *E. coli* among cancer patients; a better outcome was observed when the source of BSI was the urinary tract.<sup>214</sup>

As regards dosing, general recommendations for aminoglycoside use apply. High dose have been recommended in critically ill patients, and for severe infections caused by isolates with borderline MIC (Table 5).<sup>215–217</sup> Very high dose of amikacin (25–30 mg/kg/day) with continuous venovenous haemodiafiltration was used in 2 critically ill patients with pandrug-resistant *P. aeruginosa* with good results.<sup>217</sup>

#### *Is aztreonam useful for the treatment of invasive infections caused by MBL-producing Enterobacteriaceae?*

MBLs are characterised by the ability to hydrolyse carbapenems and all the available  $\beta$ -lactams with the exception of aztreonam. Thus, the usefulness of aztreonam for the treatment of infections due to microorganisms carrying this type of enzymes is to be considered.

Aztreonam showed a bactericidal effect in vitro against a VIM-1-producing *K. pneumoniae* strain; however, its effect was slower than that of carbapenems, and resistance to aztreonam emerged in some isolates.<sup>218</sup> In a rabbit intra-abdominal abscess model due to a carbapenem-susceptible VIM-1-producing *E. coli* strain, the efficacy of carbapenems and aztreonam was assessed; aztreonam showed the best bactericidal effect in sterilising the abscesses, although it did not reach statistical significance compared with carbapenems.<sup>219</sup> Furthermore, aztreonam was the only antibiotic which prevented death of all animals, suggesting a possible clinical benefit over carbapenems. However, there are no clinical studies evaluating the use of aztreonam in infections caused by MBL-producing *Enterobacteriaceae*.

#### *Are cephalosporins useful for the treatment of invasive infections caused by OXA-48-producing Enterobacteriaceae?*

OXA-48  $\beta$ -lactamases hydrolyse penicillins, are resistant to  $\beta$ -lactamase inhibitors, and hydrolyse carbapenems at a moderate level. Weak (cefotaxime) or no (ceftazidime) hydrolysis activity of broad-spectrum cephalosporins by this enzyme has been reported. Consequently, many OXA-48 producers that do not coproduce any ESBL (which is unfortunately not frequent) may be categorised as susceptible in vitro to broad-spectrum cephalosporins.<sup>2,136</sup> However, it is not known whether the results obtained in vitro can be translated to the in vivo setting. In an experimental peritonitis model in mice due to OXA-48-*K. pneumoniae*, ceftazidime exhibited the highest efficacy effect compared with the rest of broad-spectrum  $\beta$ -lactams tested (piperacillin-tazobactam, imipenem,

ertapenem and cefotaxime).<sup>220</sup> However, there are no clinical data evaluating the use of cephalosporins in infections caused by OXA-48-producing *Enterobacteriaceae*.

#### *When and how should tigecycline be used in invasive infections caused by MDR Enterobacteriaceae?*

Tigecycline has been tested in randomised controlled trials for complicated skin and soft tissue infections (cSSTI), community-acquired pneumonia, HAP, cIAI, and diabetic foot infections using different comparators.<sup>221–231</sup> The tigecycline dose used was 100 mg loading-dose followed by 50 mg/12 h. From the published clinical trials, information can be obtained about the clinical response in *Enterobacteriaceae* infections. Overall, 92% of potentially susceptible *Enterobacteriaceae* (excluding Proteoaceae tribe) were *E. coli* and *Klebsiella* spp. The typical MIC<sub>90</sub> was 0.5 mg/L for *E. coli* and 1–2 mg/L for *K. pneumoniae*. In none of the studies the overall clinical response rate with tigecycline was significantly different in comparison with the comparators. However, in the group of patients with ventilator-associated pneumonia (VAP), the clinical cure rate was significantly lower with tigecycline than with imipenem (31% vs 82%).<sup>224</sup> In one study of cIAI, the cure rate in the subgroup of patients with documented *E. coli* infection treated with tigecycline was 10% lower than that observed in the imipenem arm (88% vs 98%), in line with the lower clinical cure rate observed in the subgroup with complicated appendicitis (87% vs 100%).<sup>229</sup> This difference was not found in other studies in patients with cIAI. Regarding the severity of the infections, most were moderate, and immunocompromised patients were excluded.<sup>221–231</sup> Therefore, from the evidence provided by these studies it cannot be inferred that the efficacy of tigecycline in monotherapy would be the same in more severe infections.

We found 4 meta-analyses of randomised clinical trials exploring whether overall mortality and cure rates were different in patients assigned to tigecycline compared to comparators.<sup>232–235</sup> Three agreed on the finding that patients assigned to tigecycline had a higher frequency of clinical failure than patients assigned to the comparators,<sup>233,234</sup> and two of them also found higher mortality with tigecycline.<sup>234,235</sup> Tigecycline was also found to be associated with higher rate of adverse events.<sup>230–232</sup> No differences in microbiological eradication in *E. coli*<sup>222,233</sup> or *K. pneumoniae*<sup>233</sup> were observed. One of the studies also found a higher rate of clinical failure with tigecycline among patients with Gram-negative infections.<sup>234</sup> In summary, the results from meta-analyses suggest that clinical failure, adverse effects and death were more frequent among patients treated with tigecycline.

Results from animal models with *E. coli* and *K. pneumoniae* suggest that the PK/PD parameter predicting the efficacy of tigecycline is the AUC/MIC ratio, regardless of production of ESBL or carbapenemases.<sup>236</sup> An area under the curve (AUC)/MIC = 1 was associated with 50% maximum antibacterial effect for *E. coli* (eradication was associated with a AUC/MIC = 1.39 in clinical trials<sup>237,238</sup>) but was 1.6 for *K. pneumoniae*, suggesting that this microorganism requires a greater exposure. Monte Carlo simulations showed that standard tigecycline dose have a 90% probability of achieving an AUC/MIC  $\geq$  1.39 when the MIC is  $\leq$  0.5 mg/L, but only 27% if the MIC is 1 mg/L, and 0 if the MIC exceeds 1 mg/L.<sup>239</sup> It should be noted that more than 90% of *E. coli* but less than 50% of *K. pneumoniae* have a MIC  $\leq$  0.5 mg/L regardless of the mechanism of resistance.<sup>240–243</sup> Because of that, a phase II study explored the efficacy and safety of higher doses of tigecycline in patients with HAP.<sup>227</sup> Although the number of patients was too low to draw conclusions (36 and 25 subjects received 150 mg followed by 75 mg every 12 h, and 200 mg followed by 100 mg every 12 h, respectively), the clinical response rate was numerically higher in the group receiving the highest dose; the 100 mg/12 h dose was associated with a higher

incidence of gastrointestinal adverse effects (nausea, vomiting and diarrhoea).

There is little clinical experience on the efficacy of tigecycline in infections caused by ESBL-producing *Enterobacteriaceae*. Four studies including 118 patients with infections caused by ESBL-producing enterobacteria provided some additional data.<sup>244–247</sup> The most frequent infections were cIAI, cSSTI, and HAP. Clinical response rates ranged between 63% and 81%, but the percentage of patients receiving combination therapy was not always specified. The lower response rate among patients with VAP caused by *Enterobacteriaceae* found in randomised trials also occurred among those patients with VAP due to ESBL-producers (1/4 [25%] vs 6/6 [100%];  $P=0.03$  by the test Fisher's exact test).<sup>226</sup> Fifteen patients from 2 double-blind trials on cIAI had an infection caused by an ESBL-producer, and 12 (80%) showed a favourable clinical response.<sup>228,229</sup>

As regards the potential utility of tigecycline in the treatment of infections caused by CPE, available clinical data come from observational studies and case series in which patients were usually treated in combinations, in which some of them received tigecycline; most reported infections were caused by KPC-, VIM- or OXA-48-producing *K. pneumoniae*.<sup>133,138,139,164,211,248–254</sup> Overall, crude mortality among patients treated with tigecycline in monotherapy tended to be higher than in those treated with tigecycline in combination (range of mortality in studies in which data for this comparison was provided, 40–80% vs 0–33%<sup>133–135,138,139,251,252</sup>), but these data are not controlled for confounders. Because the combinations and clinical situations in which tigecycline was used are heterogenous, it is not possible to raise clear conclusions from these data.

Two additional recent retrospective studies have assessed the efficacy of different tigecycline doses for therapy of MDR Gram-negative bacteria. In one study, combination therapy with tigecycline was used at standard or high doses in 100 episodes of infection due to carbapenem-resistant *A. baumannii* or *K. pneumoniae*.<sup>255</sup> In patients with VAP, the use of high tigecycline dose (100 mg every 12 h) was the only independent predictor of clinical cure. In another study, combined therapy with tigecycline was used in 16 episodes of infection due to carbapenemase-producing *K. pneumoniae* in critically ill patients.<sup>256</sup> A crude univariate analysis showed that mortality was significantly associated with the presence of immunosuppression and mean APACHE II and SOFA scores, but not with the use of standard or high (100 mg every 12 h) tigecycline dose.

### Priority areas for future research

The panel selected the following areas as priorities for future research:

- Randomised trials comparing the clinical impact of the use of rapid diagnostic techniques in antibiotic use and clinical outcomes of patients with invasive infections caused by ESBL and carbapenemase-producing *Enterobacteriaceae*.
- Randomised controlled trials comparing the efficacy and safety of BLBLI, temocillin, and cephamycins with that of carbapenems in the treatment of invasive infections caused by ESBL-producing *Enterobacteriaceae*; ideally, the studies should be performed for specific sources of infection.
- Randomised controlled trials comparing the efficacy, safety and ecologic impact of ertapenem and group 2 carbapenems (imipenem, meropenem, doripenem) in the treatment of invasive infections caused by AmpC- and ESBL-producing *Enterobacteriaceae*.

- Randomised controlled trials comparing the efficacy and safety of fosfomicin and aminoglycosides with that of carbapenems in the treatment of cUTI caused by AmpC-, ESBL- and carbapenemase-producing *Enterobacteriaceae*.
- Randomised controlled trials comparing the efficacy of colistin monotherapy with the combinations of colistin plus carbapenem in invasive infections caused by CPE isolates with low carbapenem MIC, and colistin plus tigecycline or aminoglycosides or fosfomicin in invasive infections caused by CPE isolates with high carbapenem MIC.
- Trials with high/optimised doses of tigecycline, carbapenems and colistin in patients with invasive CPE infections. Appropriate, prospectively collected historical controls may be used as comparators.
- Clinical studies assessing the efficacy of alternative antibiotics such as aztreonam, ceftazidime/avibactam and temocillin for therapy of infections due to susceptible MDR *Enterobacteriaceae*.

### Recommendations

#### Microbiological diagnosis

- For detection of ESBL or carbapenemase-producing *Enterobacteriaceae* in surveillance samples, specific chromogenic media are recommended (BII); alternatively, molecular-based methods toward a specific target may be used (CIII).
- Confirmation of ESBL-producers should be performed in isolates showing after screening increased MIC or reduced inhibition zone to third generation cephalosporins according to either EUCAST or CLSI criteria by microdilution (Etest is to be also considered) or disk diffusion (BII).
- The recommended phenotypic confirmation tests for ESBL production are those methods which use clavulanic acid as ESBL inhibitor. Either double-disk synergy test (DDST), combined-DDST (CDDST) or microdilution can be used; the best option is probably the use of CDDST with cefotaxime, ceftazidime, and cefepime (BII).
- Confirmation of carbapenemase-producers should be performed in isolates showing after screening increased carbapenem MIC ( $>0.12 \mu\text{g/ml}$  or  $<25 \text{ mm}$  for ertapenem and/or meropenem and/or  $>1 \mu\text{g/ml}$  or  $<23 \text{ mm}$  for imipenem) (BII). Meropenem is preferred for this purpose; imipenem is not recommended as a stand-alone screening test compound (CIII). In areas with high prevalence of class D enzymes (OXA-48-like), with isolates showing reduced susceptibility to carbapenems, screening with temocillin (either  $30 \mu\text{g}$  disk diffusion or MIC,  $\leq 10 \text{ mm}$  and  $>64 \text{ mg/L}$ , respectively) in the absence of synergy of other inhibitors may be used as a first step method to identify an OXA-48 producer (BII).
- For phenotypic confirmation for carbapenemase production, the best option is the use of DDST or CDDST (which is commercially available and has been validated) using a carbapenem (usually meropenem) combined with specific class A, B, and C enzyme inhibitor (BII). However, since currently there are no available inhibitors for class D carbapenemases and temocillin as a marker is not specific for OXA-48-type carbapenemase, confirmations must be confirmed by using a genotypic method (CIII).
- In the case rapid tests are needed to confirm the presence of ESBL or carbapenemase producers, molecular methods are recommended, according to local resources (BIII).

## Therapy

### Empirical therapy

- In case of sepsis potentially caused by *Enterobacteriaceae*, clinicians should evaluate the risk of ESBL-producers considering both the epidemiological setting (e.g. rate of ESBL-producing microorganisms in a given institution) and individual risk factors (BII).
- The following individual risk factors should be assessed in all community-onset sepsis potentially caused by *Enterobacteriaceae* in order to evaluate the risk for ESBL-producers: recent use of fluoroquinolones or cephalosporins; recent hospitalisation; transfer from another healthcare facility, including long term care facilities; Charlson index >3; and age >70 years (BII). Recent travel to high endemic areas must also be considered (BIII). The same risk factors should be considered for community-onset AmpC-producers (BIII).
- ESBL-producers should be considered for empirical therapy in patients with community-onset severe sepsis or septic shock potentially caused by *Enterobacteriaceae* if presenting at least one of the previous risk factors, and in patients with non-severe sepsis if more than 2 risk factors are present (CIII).
- If ESBL-coverage is decided for a community-onset infection, a carbapenem is of choice (BII); however, in case of complicated urinary tract infection (cUTI) a  $\beta$ -lactam/ $\beta$ -lactamase inhibitor (BLBLI) plus an aminoglycoside (BII) or a third generation cephalosporin (probably ceftazidime) plus an aminoglycoside (CIII) are alternatives, according to local prevalence of susceptibility to these drugs among ESBL-producers.
- In nosocomial infections potentially caused by *Enterobacteriaceae*, individual risk factors (longer hospital stay, exposure to mechanical ventilation, and previous receipt of cephalosporins, fluoroquinolones or carbapenems) should be considered according to local epidemiology (e.g., local prevalence, outbreak) for decision about empirical therapy in order to cover for ESBL, AmpC and/or carbapenem-producers (BIII). Because of the current rates of ESBL-producers in Spanish centres, empirical therapy against ESBL-producers is recommended in all patients with nosocomial infections potentially caused by *Enterobacteriaceae* and presenting with severe sepsis or septic shock (CIII).

### Definitive treatment of invasive infections caused by ESBL-producing *Enterobacteriaceae*

- Carbapenems are the drugs of choice for invasive infections caused by ESBL- and AmpC-producing *Enterobacteriaceae* (BII). Ertapenem is chosen for patients without septic shock and isolates with MIC  $\leq 0.25$  mg/L to avoid the selective pressure on *P. aeruginosa* posed by group-2 carbapenems (CII). For other infections, imipenem or meropenem are recommended (BII); the experience with doripenem is scarce but it is probably as useful (CIII).
- In vitro active BLBLI (specifically, amoxicillin/clavulanic acid and piperacillin/tazobactam) are reasonable alternatives for bacteremic UTI or biliary tract infections caused by ESBL-producing *E. coli*, and may be used as carbapenem-sparing regimens; the recommended doses for patients with normal renal function are: 2/0.2 g/8 h in 30 min for amoxicillin/clavulanic acid and 4/0.5 g/6 h in 30 min or 4/0.5 g in extended infusion/8 h (or/6 h in critically ill patients) for piperacillin/tazobactam (CII). Data for other infection or *Enterobacteriaceae* are scarce.
- There are insufficient data to recommend the use of active cephalosporins for invasive infections caused by ESBL-producers according to EUCAST or CLSI breakpoints; however, until more data are available, we recommend caution when considering the use of these drugs; their use is only recommended as an

alternative option for the treatment of non-severe UTI sepsis in low risk patients (CIII).

- There are insufficient data to recommend the use of cephamycins, fluoroquinolones, aminoglycosides, trimethoprim-sulfamethoxazole, colistin or fosfomycin. For fully susceptible isolates there is no reason to expect different efficacy than in non-ESBL-producers (CIII).

### Treatment of invasive infections caused by carbapenemase-producing *Enterobacteriaceae* (CPE)

- Therapy must be individualised according to susceptibility results, source of infection and severity of disease (CII). According to general knowledge in management of infections, source control and support therapy are key aspects in the management of these infections (BII).
- Combination therapy is recommended for severe infections caused by KPC-producing *K. pneumoniae* (CII), and possibly for other carbapenemase-producing *Enterobacteriaceae* until more data are available (CII). There are no data to support combination therapy for patients with mild infections for which fully active drugs, useful for the specific type of infection, are available; therefore, we recommend monotherapy for such infections, and particularly for non-severe UTIs (CIII).
- Monotherapy with a carbapenem is not recommended for patients with invasive infections caused by CPE but may be considered in cases of mild invasive infections if adequate source control is readily achieved and the isolate is susceptible according to EUCAST or CLSI breakpoints; the typical example would be sepsis from the urinary tract, without urinary tract obstruction nor severe sepsis or septic shock (CIII).
- For patients in which combination therapy is indicated, a regimen with a carbapenem (see preferred drug and recommended dose below) plus one or two fully active drugs (including colistin, tigecycline, an aminoglycoside or fosfomycin, the latter preferably as a third drug) is recommended if the carbapenem MIC is  $\leq 8$  mg/L; this applies mainly to patients with severe infections caused by KPC-producing *K. pneumoniae* (BII). We suggest a similar approach for other carbapenemases until more data are available (CIII). No recommendation can be given for using the combination of ertapenem plus doripenem or meropenem for KPC-producers (unresolved issue).
- There are not enough data to recommend including a carbapenem in combination regimens if minimal inhibitory concentration (MIC) is  $>8$  mg/L; if this is the case, carbapenems are probably useless, particularly if MIC is  $>16$  mg/L; we recommend including at least two fully active drugs in the combination regimen according to susceptibility, testing and source of infection (drugs to be considered: colistin, aminoglycosides, fosfomycin and tigecycline) (CIII).
- Patients with less severe invasive infections and cUTIs might be treated with carbapenem-sparing combinations (drugs to be considered: colistin, aminoglycosides, fosfomycin, tigecycline – the latter not for UTI) or even monotherapy (see above) (CIII).
- Dosing of all administered drugs should be optimised to increase the probability of reaching the appropriate pharmacodynamics target (BII); in the case of carbapenems, we recommend using meropenem at 2 g every 8 h in extended infusion (BII).

### Colistin

- Colistin should be preserved for treating infections produced by *Enterobacteriaceae* strains showing resistance to all  $\beta$ -lactam antibiotics (CIII).
- Colistin is suggested as part of the empirical treatment of patients with severe infections if participation of CPE is suspected, such as in outbreaks or colonised patients (CIII).

- When using colistin and until more data are available, we recommend the use of a loading dose of 9 MU and subsequent high, extended-interval maintenance doses (4.5 MU/12 h) in critically ill patients and patients with severe sepsis or septic shock with creatinine clearance above 50 ml/min; maintenance dose should be individually adjusted according to creatinine clearance according to published nomograms (CIII).
- Data to recommend a loading dose in non-critically ill patients with non-severe infections are unavailable (unresolved issue); maintenance dosing with 4.5 MU/12 h (or alternatively 3 MU/8 h) is suggested, but renal function should be closely monitored (CIII).
- No recommendations can be given for patients with extreme weights (unresolved issue).
- We recommend 1–2 MU of colistin every 12 h for patients undergoing intermittent haemodialysis. Whenever possible, haemodialysis should be conducted at the end of the dosing interval to minimise the clearance of colistin. If this is not possible, a supplemental dose at the end of the dialysis should be considered (CIII). For patients undergoing continuous venovenous haemodiafiltration, even though the data are not consistent, a dose of 9 MU/day is suggested (CIII).

#### Fosfomycin

- Experience with fosfomycin for the treatment of invasive infections caused by MDR and XDR *Enterobacteriaceae* is limited; however, in patients with limited options, fosfomycin (4–6 g every 6 h to 8 g every 8 h) may be considered as part of a combination regimen including at least one more active agent (CIII).

#### Aminoglycosides

- Based on the experience of non MDR *Enterobacteriaceae* infections, monotherapy with an active aminoglycoside may be considered for the treatment of cUTI caused by MDR and XDR *Enterobacteriaceae*. Toxicity should be closely monitored (BII).
- Monotherapy with aminoglycosides for other invasive infections is not recommended. For such infections, combination therapy with other drug is suggested (BII). However, aminoglycosides are to be considered as an accompanying agent in all combination regimens according to the susceptibility results with close monitoring of toxicity (CIII).

#### Aztreonam and cephalosporins for susceptible, CPE

- There is no clinical experience with aztreonam or cephalosporins for the treatment of invasive infections due to susceptible MBL- or OXA-48-producing *Enterobacteriaceae*, respectively. Very scarce in vitro and animal model data suggest that they may be useful; if considered, we recommend using these drugs in combination except in cUTI (CIII).

#### Tigecycline

- Tigecycline monotherapy should be avoided whenever possible (AI); exceptions may be selected patients with mild cIAI and cSSI infections caused by XDR *Enterobacteriaceae* with other few adequate alternative options (CIII).
- Tigecycline should be considered as part of a combination regimen in patients with infections other than UTI caused by *Enterobacteriaceae* producing either ESBLs (if a carbapenem-spare regimen is to be used) or carbapenemases when tigecycline MIC is  $\leq 1$  mg/L (CIII).
- Single dose of tigecycline (150 mg loading dose followed by 75 mg/12 h, or 200 mg loading dose followed by 100 mg/12 h) should be considered for patients in septic shock, VAP or *Enterobacteriaceae* with MIC  $\geq 1$  mg/L, but adverse events should be carefully monitored (BIII).

#### Conflict of interest

JRB was consultant for MSD, AstraZeneca, Pfizer, Roche, Novartis, Astellas and Anchaogen; speaker for MSD, AstraZeneca, Pfizer, Novartis and Astellas; and received research grants from Novartis and Gilead. CG was speaker for Novartis, Pfizer and Astellas; and received a research grant from Astellas. JPH was speaker and Basilea for MSD, Astellas, Astra-Zeneca, Novartis, Pfizer and Janssen; and received research grants from Pfizer. All other authors have no conflict of interest.

#### Acknowledgements

Supported by the Spanish Society of Clinical Microbiology and Infectious Diseases, and Ministerio de Economía y Competitividad, Instituto de Salud Carlos III – co-financed by European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015).

We are grateful to Belén Padilla, Jose María Gutiérrez and Juan E. Losa for their valuable comments on the manuscript.

#### Appendix 1. Abbreviations

- BLBLI:  $\beta$ -lactam/ $\beta$ -lactam inhibitor combinations
- BSI: bloodstream infections
- cIAI: complicated intraabdominal infection
- cUTI: complicated urinary tract infection
- CLSI: Clinical and Laboratory Standards Institute
- CPE: carbapenemase-producing *Enterobacteriaceae*
- CRE: carbapenem-resistant *Enterobacteriaceae*
- ESBL: extended-spectrum  $\beta$ -lactamase
- EUCAST: European Committee for Antimicrobial Susceptibility Testing
- GNB: Gram negative bacilli
- HAP: hospital-acquired pneumonia
- IAI: intraabdominal infection
- ICU: intensive care unit
- KPC: *Klebsiella pneumoniae* carbapenemase
- MDR: multi-drug resistant
- MIC: minimum inhibitory concentration
- MBL: metallo- $\beta$ -lactamase
- PK/PD: pharmacokinetic/pharmacodynamic
- UTI: urinary tract infection
- VAP: ventilator-associated pneumonia
- XDR: extensively drug resistant

#### References

1. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: an emerging public-health concern. *Lancet Infect Dis.* 2008;8:159–66.
2. Tzouveleakis LS, Markogiannakis A, Psychogiou M, Tassios PT, Daikos GL. Carbapenemases in *Klebsiella pneumoniae* and other *Enterobacteriaceae*: an evolving crisis of global dimensions. *Clin Microbiol Rev.* 2012;25:682–707.
3. ECDC/EMA Joint Technical Report. The bacterial challenge: time to react. Available from: [http://www.ecdc.europa.eu/en/publications/Publications/0909\\_TER\\_The\\_Bacterial\\_Challenge\\_Time\\_to\\_React.pdf](http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf)
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESCAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis.* 2009;48:1–12.
5. Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. *Clin Infect Dis.* 2012;55:1031–46.
6. Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. *Lancet Infect Dis.* 2013;13:269–75.

7. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae* and patient outcome: a meta-analysis. *J Antimicrob Chemother.* 2012;**67**:1311–20.
8. Vardakas KJ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug. *J Infect.* 2013;**66**:401–14.
9. EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1; 2013. Available from: <http://www.eucast.org/>
10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Twenty-third information supplement. M100-S23; 2013, January.
11. Mouton JW, Brown DF, Apfalter P, Cantón R, Giske CG, Ivanova M, et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. *Clin Microbiol Infect.* 2012;**18**:E37–45.
12. Livermore DM, Andrews JM, Hawkey PM, Ho PL, Keness Y, Doi Y, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly. *J Antimicrob Chemother.* 2012;**67**:1569–77.
13. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012;**18**:268–81.
14. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. *Clin Infect Dis.* 2011;**52**:285–92.
15. Gazin M, Paesch F, Goossens H, Malhotra-Kumar S, MOSAR WP2 and SATURN WP1 Study Teams. Current trends in culture-based and molecular detection of extended-spectrum  $\beta$ -lactamase-harboring and carbapenem-resistant *Enterobacteriaceae*. *J Clin Microbiol.* 2012;**50**:1140–6.
16. Navarro F, Calvo J, Cantón R, Fernández-Cuenca F, Mirelis B. Detection of resistance phenotypes in gram-negative bacteria. *Enferm Infecc Microbiol Clin.* 2011;**29**:524–34.
17. Willems E, Verhaegen J, Magerman K, Nys S, Cartuyvels R. Towards a phenotypic screening strategy for emerging  $\beta$ -lactamases in Gram-negative bacilli. *Int J Antimicrob Agents.* 2013;**41**:99–109.
18. Garrec H, Drieux-Rouzet L, Golmard JL, Jarlier V, Robert J. Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by *Enterobacteriaceae*. *J Clin Microbiol.* 2011;**49**:1048–57.
19. Wintermans BB, Reuland EA, Wintermans RG, Bergmans AM, Kluytmans JA. The cost-effectiveness of ESBL detection: towards molecular detection methods. *Clin Microbiol Infect.* 2013;**19**:662–5.
20. Giske CG, Gezelius L, Samuelsen Ø, Warner M, Sundsfjord A, Woodford N. A sensitive and specific phenotypic assay for detection of metallo- $\beta$ -lactamase and KPC in *Klebsiella pneumoniae* with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. *Clin Microbiol Infect.* 2011;**17**:552–6.
21. Tsakris A, Themeli-Digalaki K, Poulou A, Vrioni G, Voulgari E, Koumaki V, et al. Comparative evaluation of combined-disk tests using different boronic acid compounds for detection of *Klebsiella pneumoniae* carbapenemase-producing *Enterobacteriaceae* clinical isolates. *J Clin Microbiol.* 2011;**49**:2804–9.
22. Girlich D, Poirel L, Nordmann P. Comparison of the SUPERCARBA, CHROMagar KPC, and Brilliance CRE screening media for detection of *Enterobacteriaceae* with reduced susceptibility to carbapenems. *Diagn Microbiol Infect Dis.* 2013;**75**:214–7.
23. Papadimitriou-Olivgeris M, Christodoulou C, Christofidou M, Hey J, Zambardi G, et al. Improvement of chromID<sup>®</sup> CARBA medium for carbapenemase-producing *Enterobacteriaceae* detection during rectal screening. *Eur J Clin Microbiol Infect Dis.* 2014;**33**:35–40.
24. Girlich D, Anglade C, Zambardi G, Nordmann P. Comparative evaluation of a novel chromogenic medium (chromID OXA-48) for detection of OXA-48 producing *Enterobacteriaceae*. *Diagn Microbiol Infect Dis.* 2013;**77**:296–300.
25. Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemase-producing *Enterobacteriaceae*. *Emerg Infect Dis.* 2012;**18**:1503–7.
26. Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A. Sensitive screening tests for suspected class A carbapenemase production in species of *Enterobacteriaceae*. *J Clin Microbiol.* 2009;**47**:1631–9.
27. van Dijk K, Voets GM, Scharringa J, Voskuil S, Fluit AC, Rottier WC, et al. A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in *Enterobacteriaceae* using phenyl boronic acid, dipicolinic acid and temocillin. *Clin Microbiol Infect.* 2014;**20**:345–9.
28. Nordmann P, Poirel L. Strategies for identification of carbapenemase-producing *Enterobacteriaceae*. *J Antimicrob Chemother.* 2013;**68**:487–9.
29. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in *Enterobacteriaceae*. *J Antimicrob Chemother.* 2010;**65**:490–5.
30. Priyadharsini RI, Kavitha A, Rajan R, Mathavi S, Rajesh KR. Prevalence of bla (CTX M) carriage rates of CTX-M ESBL-producing *Escherichia coli* in a specific population group in Birmingham, UK. *J Antimicrob Chemother.* 2012;**67**:1108–13.
31. Rimrang B, Chanawong A, Lulitanond A, Wilailuckana C, Charoensri N, Sribenjalux P, et al. Emergence of NDM-1- and IMP-14a-producing *Enterobacteriaceae* in Thailand. *J Antimicrob Chemother.* 2012;**67**:2626–30.
32. Hong SS, Kim K, Huh JY, Jung B, Kang MS, Hong SC. Multiplex PCR for rapid detection of genes encoding class A carbapenemases. *Ann Lab Med.* 2012;**32**:359–61.
33. Sheng WH, Badal RE, Hsueh PR, SMART program. Distribution of extended-spectrum beta-lactamases, AmpC beta-lactamases, and carbapenemases among *Enterobacteriaceae* isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). *Antimicrob Agents Chemother.* 2013;**57**:2981–8.
34. Kaur M, Aggarwal A. Occurrence of the CTX-M, SHV and the TEM genes among the extended spectrum  $\beta$ -lactamase producing isolates of *Enterobacteriaceae* in a tertiary care hospital of North India. *J Clin Diagn Res.* 2013;**7**:642–5.
35. Avlami A, Bekris S, Ganteris G, Kraniotaki E, Malamou-Lada E, Orfanidou M, et al. Detection of metallo- $\beta$ -lactamase genes in clinical specimens by a commercial multiplex PCR system. *J Microbiol Methods.* 2010;**83**:185–7.
36. Brolund A, Wisell KT, Edquist PJ, Elfstrom L, Walder M, Giske CG. Development of a real-time SYBRGreen PCR assay for rapid detection of acquired AmpC in *Enterobacteriaceae*. *J Microbiol Methods.* 2010;**82**:229–33.
37. Alfaresi MS, Elkoush AA. Real-time polymerase chain reaction for rapid detection of genes encoding SHV extended-spectrum beta-lactamases. *Indian J Med Microbiol.* 2010;**28**:332–6.
38. Chen L, Chavda KD, Mediavilla JR, Zhao Y, Fraimow KP, Jenkins SG, et al. Multiplex real-time PCR for detection of an epidemic KPC-producing *Klebsiella pneumoniae* ST258 clone. *Antimicrob Agents Chemother.* 2012;**56**:3444–7.
39. Swayne RL, Ludlam HA, Shet VG, Woodford N, Curran MD. Real-time TaqMan PCR for rapid detection of genes encoding five types of non-metallo (class A and D) carbapenemases in *Enterobacteriaceae*. *Int J Antimicrob Agents.* 2011;**38**:35–8.
40. Oxacelay C, Ergani A, Naas T, Nordmann P. Rapid detection of CTX-M-producing *Enterobacteriaceae* in urine samples. *J Antimicrob Chemother.* 2009;**64**:986–9.
41. Singh K, Mangold KA, Wyant K, Schora DM, Voss B, Kaul KL, et al. Rectal screening for *Klebsiella pneumoniae* carbapenemase: comparison of real-time PCR and culture using two selective screening agar plates. *J Clin Microbiol.* 2012;**50**:2596–600.
42. Hindiyeh M, Smollan G, Grossman Z, Ram D, Robinov V, Belausov N, et al. Rapid detection of blaKPC carbapenemase genes by internally controlled real-time PCR assay using bactec blood culture bottles. *J Clin Microbiol.* 2011;**49**:2480–4.
43. Naas T, Cotellon G, Ergani A, Nordmann P. Real-time PCR for detection of blaOXA-48 genes from stools. *J Antimicrob Chemother.* 2013;**68**:101–4.
44. Vasoo S, Cunningham SA, Kohner PC, Mandrekar JM, lolans K, Hayden MH, et al. Rapid and direct real-time detection of blaKPC and blaNDM from surveillance samples. *J Clin Microbiol.* 2013;**51**:3609–15.
45. Richter SN, Biasolo MA, Bartolini A, Cavallaro A, Palu G. Ultrarapid detection of blaKPC<sub>1/2-12</sub> from periastral and nasal swabs by use of real-time PCR. *J Clin Microbiol.* 2012;**50**:1718–20.
46. McEwan AS, Derome A, Meunier D, Burns DJ, Woodford N, Dogsa AR. Evaluation of the NucliSENS EasyQ KPC assay for detection of *Klebsiella pneumoniae* carbapenemase-producing *Enterobacteriaceae*. *J Clin Microbiol.* 2013;**51**:1948–50.
47. Cohen Stuart J, Dieerikx C, Al Naiemi N, Karczarek A, Van Hoek AH, Vos P, et al. Rapid detection of TEM, SHV and CTX-M extended-spectrum beta-lactamases in *Enterobacteriaceae* using ligation-mediated amplification with microarray analysis. *J Antimicrob Chemother.* 2010;**65**:1377–81.
48. Platteel TN, Stuart JW, Voets GM, Scharringa J, van de Sande N, Fluit AC, et al. Evaluation of a commercial microarray as a confirmation test for the presence of extended-spectrum beta-lactamases in isolates from the routine clinical setting. *Clin Microbiol Infect.* 2011;**17**:1435–8.
49. Lascols C, Hackel M, Marshall SH, Hujer AM, Bouchillon S, Badal R, et al. Increasing prevalence and dissemination of NDM-1 metallo-beta-lactamase in India: data from the SMART study (2009). *J Antimicrob Chemother.* 2011;**66**:1992–7.
50. De Boeck H, Lunguya O, Muyembe JJ, Glupczynski Y, Jacobs J. Presence of extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in waste waters, Kinshasa, the Democratic Republic of the Congo. *Eur J Clin Microbiol Infect Dis.* 2012;**31**:3085–8.
51. Naas T, Cuzon G, Bogaerts P, Glupczynski Y, Nordmann P. Evaluation of a DNA microarray (Check-MDR CT102) for rapid detection of TEM, SHV, and CTX-M extended-spectrum  $\beta$ -lactamases and of KPC, OXA-48, VIM, IMP, and NDM-1 carbapenemases. *J Clin Microbiol.* 2011;**49**:1608–13.
52. Woodford N, Warner M, Pike R, Zhang J. Evaluation of a commercial microarray to detect carbapenemase-producing *Enterobacteriaceae*. *J Antimicrob Chemother.* 2011;**66**:2887–8.
53. Bush K, Pannell M, Lock JL, Queenan AM, Jorgensen JH, Lee RM, et al. Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. *Int J Antimicrob Agents.* 2013;**41**:1–4.
54. Jones CH, Ruzin A, Tuckman M, Visalli MA, Petersen PJ, Bradford PA. Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155. *Antimicrob Agents Chemother.* 2009;**53**:977–86.
55. Burckhardt I, Zimmermann S. Using matrix-assisted laser desorption/ionization-time of flight mass spectrometry to detect carbapenem resistance within 1 to 2.5 hours. *J Clin Microbiol.* 2011;**49**:3321–4.



57. Hrabak J, Studentova V, Walkova R, Zemlicková H, Jakubu V, Chudácková E, et al. Detection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by matrix-assisted laser desorption/ionization-time of flight mass spectrometry. *J Clin Microbiol.* 2012;50:2441–3.
58. Spinler K, Schubert S, Weller U, Boogen C, Kostrzewa M. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry-based functional assay for rapid detection of resistance against  $\beta$ -lactam antibiotics. *J Clin Microbiol.* 2012;50:927–37.
59. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest.* 2009;136:1237–48.
60. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing *Enterobacteriaceae*: importance of inadequate initial antimicrobial treatment. *Antimicrob Agents Chemother.* 2014;51:1987–94.
61. Dortet L, Cuzon G, Nordmann P. Dissemination of carbapenemase-producing *Enterobacteriaceae* in France, 2012. *J Antimicrob Chemother.* 2014;69:623–7.
62. Nicolau-Chanoine MH, Jarlier V. Extended-spectrum beta-lactamases in long-term-care facilities. *Clin Microbiol Infect.* 2008;14 Suppl. 1:111–6.
63. Lin MY, Lyles-Banks RD, Lolans K, Hines DW, Spear JB, Petrak R, et al. The importance of long-term acute care hospitals in the regional epidemiology of *Klebsiella pneumoniae* carbapenemase-producing *Enterobacteriaceae*. *Clin Infect Dis.* 2013;57:1246–52.
64. Rodríguez-Baño J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. *Expert Rev Anti Infect Ther.* 2008;6:671–83.
65. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *Arch Intern Med.* 2008;168:1897–902.
66. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruiz M, Peña C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing *Escherichia coli*: risk factors and prognosis. *Clin Infect Dis.* 2010;50:40–8.
67. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Cisneros JM, Peña C, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing *Escherichia coli*. *J Clin Microbiol.* 2010;48:1726–31.
68. Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, et al. Identification of extended-spectrum beta-lactamase-producing *Enterobacteriaceae* into the hospital. *Clin Infect Dis.* 2006;42:925–34.
69. Tumbarello M, Trecarichi EM, Bassetti M, De Rosa FG, Spanu T, Di Meco E, et al. Identifying patients harboring ESBL-producing *Enterobacteriaceae* on hospital admission: derivation and validation of a scoring system. *Antimicrob Agents Chemother.* 2011;55:3485–90.
70. Johnson SW, Anderson DJ, May DB, Drew RH. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae* on hospital admission. *Infect Control Hosp Epidemiol.* 2013;34:385–92.
71. Slekovec C, Bertrand X, Leroy J, Faller JP, Talon D, Hocquet D. Identifying patients harboring extended-spectrum- $\beta$ -lactamase-producing *Enterobacteriaceae* on hospital admission is not that simple. *Antimicrob Agents Chemother.* 2012;56:2218–9.
72. van der Bij AK, Pitout JD. The role of international travel in the worldwide spread of multiresistant *Enterobacteriaceae*. *J Antimicrob Chemother.* 2012;67:2090–100.
73. Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Muñoz A, et al. Analysis of 4758 *Escherichia coli* bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. *J Antimicrob Chemother.* 2009;63:568–74.
74. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Perea E, Pérez-Cano R, et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing *Escherichia coli* as a cause of nosocomial infection or colonization: implications for control. *Clin Infect Dis.* 2006;42:37–45.
75. Peña C, Gudiol C, Tubau F, Saballs M, Pujol M, Dominguez MA, et al. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing *Escherichia coli* among hospitalised patients. *Clin Microbiol Infect.* 2006;12:279–84.
76. Martínez JA, Aguilar J, Almela M, Marco F, Soriano A, López F, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing *Escherichia coli* or *Klebsiella* spp. in patients with bacteraemia. *J Antimicrob Chemother.* 2006;58:1082–5.
77. Peña C, Pujol M, Ardanuy C, Ricart A, Pallarés R, Liñares J, et al. An outbreak of hospital-acquired *Klebsiella pneumoniae* bacteraemia, including strains producing extended-spectrum beta-lactamase. *J Hosp Infect.* 2001;47:53–9.
78. Lee CH, Lee YT, Kung CH, Wu F, Kuo SC, Chen TL, et al. Risk factors of community-onset urinary tract infections caused by multidrug-resistant AmpC  $\beta$ -lactamase-producing *Enterobacteriaceae*. *J Microbiol Immunol Infect.* 2013; pii:S1684-1182(13)00155-2.
79. Park YS, Yoo S, Seo MR, Kim JY, Cho YK, Pai H. Risk factors and clinical features of infections caused by plasmid-mediated AmpC beta-lactamase-producing *Enterobacteriaceae*. *Int J Antimicrob Agents.* 2009;34:38–43.
80. Linares L, Cervera C, Cofán F, Lizaso D, Marco F, Ricart MJ, et al. Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing gram-negative rods in renal transplantation. *Am J Transplant.* 2008;8:1000–5.
81. Pai H, Kang CI, Byeon JH, Lee KD, Park WB, Kim HB, et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2004;48:3720–8.
82. Correa L, Martzouk MD, Siqueira I, Pasternak J, Gales AC, Silva CV, et al. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant *Klebsiella pneumoniae* infection. *BMC Infect Dis.* 2013;13:80.
83. Orsi GB, Bencardino A, Otera A, Carattoli A, Venditti C, Falcone M, et al. Patient risk factors for outer membrane permeable KPC-producing carbapenem-resistant *Klebsiella pneumoniae* isolation: results of a double case-control study. *Infection.* 2013;41:61–7.
84. Tuon FF, Rocha JL, Toledo P, Arend LN, Dias CH, Leite TM, et al. Risk factors for KPC-producing *Klebsiella pneumoniae* bacteremia. *Braz J Infect Dis.* 2012;16:416–9.
85. Patel N, Harrington S, Dihmess A, Woo B, Masoud R, Martis P, et al. Clinical epidemiology of carbapenem-intermediate or -resistant *Enterobacteriaceae*. *J Antimicrob Chemother.* 2011;66:1600–8.
86. Mouloudi E, Protonotariou E, Zagorianou E, Iosifidis E, Karapanagiotou A, Giasnetsova T, et al. Bloodstream infections caused by metallo- $\beta$ -lactamase/*Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. *Infect Control Hosp Epidemiol.* 2010;31:1250–6.
87. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*. *Infect Control Hosp Epidemiol.* 2009;30:1180–5.
88. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among *Klebsiella pneumoniae* isolates: risk factors, molecular characteristics, and susceptibility patterns. *Infect Control Hosp Epidemiol.* 2009;30:666–71.
89. Sánchez-Romero I, Asensio A, Oteo J, Muñoz-Algarra M, Isidoro B, Vindel A, et al. Nosocomial outbreak of VIM-1-producing *Klebsiella pneumoniae* isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome. *Antimicrob Agents Chemother.* 2012;56:420–7.
90. Daikos GK, Vryonis E, Psychogiou M, Tzouveleki LS, Liatsi S, Petrikos P, et al. Risk factors for bloodstream infection with *Klebsiella pneumoniae* producing VIM-1 metallo-beta-lactamase. *J Antimicrob Chemother.* 2010;65:784–8.
91. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev.* 2005;18:657–86.
92. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenem versus alternative antibiotics for treatment of bacteraemia due to *Enterobacteriaceae* producing extended-spectrum  $\beta$ -lactamases: a systematic review and meta-analysis. *J Antimicrob Chemother.* 2012;67:2793–803.
93. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cephalosporin-susceptible extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: MIC matters. *Clin Infect Dis.* 2013;56:488–95.
94. Yang CC, Li SH, Chuang FR, Chen CH, Lee CH, Chen JB, et al. Discrepancy between effects of carbapenems and fentanyl in treating nosocomial hemodialysis access-related bacteremia and secondary to extended spectrum beta-lactamase producing *Klebsiella pneumoniae* in patients on maintenance hemodialysis. *BMC Infect Dis.* 2012;12:206.
95. Wu UI, Chen WC, Yang CS, Wang JL, Hu FC, Chang SC, et al. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing *Escherichia coli*: a propensity score analysis. *Int J Infect Dis.* 2012;16:e47–52.
96. Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R. Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant *Enterobacteriaceae*: analysis of six phase 3 clinical studies. *Antimicrob Agents Chemother.* 2010;54:2119–24.
97. Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima AL, et al. Carbapenem stewardship: does ertapenem affect *Pseudomonas* susceptibility to other carbapenems. A review of the evidence. *Int J Antimicrob Agents.* 2012;39:11–5.
98. Sousa D, Castelo-Corral L, Gutiérrez-Urbón JM, Molina F, López-Calviño B, Bou G, et al. Impact of ertapenem use on *Pseudomonas aeruginosa* and *Acinetobacter baumannii* imipenem susceptibility rates: collateral damage or positive effect on hospital ecology. *J Antimicrob Chemother.* 2013;68:1917–25.
99. Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ. Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review. *Expert Rev Anti Infect Ther.* 2013;11:69–78.
100. Lee CM, Lai CC, Wang YY, Lee MC, Hsueh PR. Introduction of susceptibility profiles of Gram-negative bacteria before and after the introduction of ertapenem at a medical center in northern Taiwan from 2004 to 2010. *Diagn Microbiol Infect Dis.* 2013;75:94–100.
101. Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC. Carbapenem therapy for bacteremia due to extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*. *Diagn Microbiol Infect Dis.* 2011;70:150–3.
102. Collins VL, Marchaim D, Pogue JM, Moshos J, Bhemreddy S, Sunkara B, et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum- $\beta$ -lactamase-producing *Enterobacteriaceae*. *Antimicrob Agents Chemother.* 2012;56:2173–7.

103. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Carbapenem therapy for bacteremia due to extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*: implications of ertapenem susceptibility. *Antimicrob Agents Chemother.* 2012;56:2888–93.
104. Elliott E, Brink AJ, van Zeeve J, Els Z, Woodford N, Turton J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by *Klebsiella pneumoniae* with an extended-spectrum beta-lactamase. *Clin Infect Dis.* 2006;42:e95–8.
105. Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodríguez MC, Velasco M, et al. Emergence of imipenem resistance in clinical *Escherichia coli* during therapy. *Int J Antimicrob Agents.* 2008;32:534–7.
106. Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. *Ann Pharmacother.* 2008;42:207–12.
107. Lee CH, Su LH, Lin WC, Tang YF, Liu JW. Refractory vertebral osteomyelitis due to CTX-M-14-producing *Escherichia coli* at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen. *Int J Infect Dis.* 2010;14 Suppl. 3:e183–6.
108. Skurnik D, Lasocki S, Brelmont S, e183–6. Development of ertapenem resistance in a patient with mediastinitis caused by *Klebsiella pneumoniae* producing an extended-spectrum beta-lactamase. *J Med Microbiol.* 2010;59:115–9.
109. Bassetti M, Righi E, Fasce R, Molinari MP, Rosso R, Di Biagio A, et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. *J Antimicrob Chemother.* 2007;60:433–5.
110. Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. *J Antimicrob Chemother.* 2010;65:1510–3.
111. MacGowan A. Breakpoints for extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: pharmacokinetic/pharmacodynamic considerations. *Clin Microbiol Infect.* 2008;14 Suppl. 1:166–8.
112. Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and  $\beta$ -lactam/ $\beta$ -lactamase inhibitors in the treatment of infections caused by extended-spectrum- $\beta$ -lactamase-producing *Enterobacteriaceae*. *J Antimicrob Chemother.* 2014;69:871–80.
113. Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, et al. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing *Enterobacter aerogenes* in severely-ill patients. *Clin Microbiol Infect.* 2006;12:56–62.
114. Bin C, Hui W, Renyuan Z, Yongzhong N, Xiuli X, Tingchun X, et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing *Escherichia coli*. *Diagn Microbiol Infect Dis.* 2006;56:351–7.
115. Rodríguez-Baño J, Picón E, Navarro MD, López-Cerero L, Pascual A, ESBL-REIPI Group. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*. *Clin Microbiol Infect.* 2012;18:894–900.
116. Chopra T, Marchaim D, Veltman J, Johnson P, Zhao JJ, Tansek R, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum- $\beta$ -lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli*. *Antimicrob Agents Chemother.* 2012;56:3936–42.
117. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monocicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: MIC matters. *Clin Infect Dis.* 2013;56:488–95.
118. Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-producing *Klebsiella pneumoniae* bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. *J Antimicrob Chemother.* 2006;58:1074–7.
119. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing *Enterobacteriaceae*. *Int J Infect Dis.* 2013;17:e159–63.
120. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual A, Extended-spectrum beta-lactamase-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group.  $\beta$ -Lactam/ $\beta$ -lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*: a post hoc analysis of prospective cohorts. *Clin Infect Dis.* 2012;54:167–74.
121. Retamar P, López-Cerero L, Muniain MA, Pascual A, Rodríguez-Baño J, ESBL-REIPI/GEIH Group. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli*. *Antimicrob Agents Chemother.* 2013;57:3402–4.
122. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. *Clin Infect Dis.* 2013;56:272–82.
123. Giamarellou H. Beta-lactams without a suicide inhibitor. *Clin Microbiol Infect.* 2008;14 Suppl. 1:194–7.
124. Balakrishnan I, Awad-Ei-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC  $\beta$ -lactamase-producing *Enterobacteriaceae*. *J Antimicrob Chemother.* 2011;66:2628–31.
125. Patel G, Bonomo RA. State report on carbapenems: challenges and prospects. *Expert Rev Anti Infect Ther.* 2011;9:550–70.
126. Delgado-Valverde M, Sojo-Dorado J, Pascual A, Rodríguez-Baño J. Clinical management of infections caused by multidrug-resistant *Enterobacteriaceae*. *Ther Adv Infect Dis.* 2013;1:49–69.
127. Adams-Haduch JM, Potoski BA, Sidjabat HE, Paterson DL, Doi Y. Activity of temocillin against KPC-producing *Klebsiella pneumoniae* and *Escherichia coli*. *Antimicrob Agents Chemother.* 2009;53:2700–1.
128. Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, et al. Carbapenem-non-susceptible *Enterobacteriaceae* in Europe: conclusions from a meeting of national experts. *Euro Surveill.* 2010;15, pii:19711.
129. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. *Clin Microbiol Infect.* 2010;16:102–11.
130. Nordman P, Cuzon G, Naas T. The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria. *Lancet Infect Dis.* 2009;9:228–36.
131. Cornaglia G, Giamarellou H, Rossolini GM, Mettallo-B-lactamases: a last frontier for beta-lactams. *Lancet Infect Dis.* 2011;11:381–93.
132. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. *J Antimicrob Chemother.* 2012;67:1597–606.
133. Tumbarello M, Viale P, Viscoli C, Treccarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by KPC-producing *Klebsiella pneumoniae*: importance of combination therapy. *Clin Infect Dis.* 2012;55:943–50.
134. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing *Klebsiella pneumoniae*: superiority of combination antimicrobial regimens. *Antimicrob Agents Chemother.* 2012;56:2108–13.
135. Zarkotou O, Pournaras S, Tseliotti P, Dragoumanos V, Piritriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing *Klebsiella pneumoniae* and impact of appropriate antimicrobial treatment. *Clin Microbiol Infect.* 2011;17:1798–803.
136. Paño-Pardo JR, Ruiz-Carrasco G, Navarro-San Francisco C, Gómez-Gil R, Mora-Rillo M, Romero-Gómez MP, et al. Infections caused by OXA-48-producing *Klebsiella pneumoniae* in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak. *J Antimicrob Chemother.* 2012;68:89–96.
137. Daikos GL, Petrikos P, Psychogiou M, Kosmidis C, Vryonis E, Skoutelis A, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with *Klebsiella pneumoniae* bloodstream infections. *Antimicrob Agents Chemother.* 2009;53:1868–73.
138. Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP, Moreno-Ramos F, Rico-Nieto A, Ruiz-Carrasco G, et al. Bacteraemia due to OXA-48-carbapenemase-producing *Enterobacteriaceae*: a major clinical challenge. *Clin Microbiol Infect.* 2013;19:E72–9.
139. Daikos GL, Tsaousi S, Tzouvelelis LS, Anyfantis I, Psychogiou M, Argyropoulou A, et al. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infections: lowering mortality by antibiotic combination therapy and the role of carbapenems. *Antimicrob Agents Chemother.* 2014;58:2322–8.
140. Hirsch EB, Tam VH. Detection and treatment options for *Klebsiella pneumoniae* carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. *J Antimicrob Chemother.* 2010;65:1119–25.
141. Lee GC, Burgess DS. Treatment of *Klebsiella pneumoniae* carbapenemase (KPC) infections: a review of published cases series and case reports. *Ann Clin Microbiol Infect.* 2012;11:32.
142. Akova M, Daikos GL, Tzouvelelis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. *Clin Microbiol Infect.* 2012;18:439–48.
143. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant *Enterobacteriaceae*: systematic evaluation of the available evidence. *Antimicrob Agents Chemother.* 2014;58:654–63.
144. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. *J Antimicrob Chemother.* 2014;69:2305–9.
145. Cuzon G, Naas T, Truong H, Villegas MV, Wisel KT, Carmeli Y, et al. Worldwide diversity of *Klebsiella pneumoniae* that produce beta-lactamase blaKPC-2 gene. *Emerg Infect Dis.* 2010;16:1349–56.
146. Daikos GL, Karabinis A, Paramythiotou E, Syriopoulou VP, Kosmidis C, Avlami A, et al. VIM-1-producing *Klebsiella pneumoniae* bloodstream infections: analysis of 28 cases. *Int J Antimicrob Agents.* 2007;29:471–3.
147. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis.* 2010;10:597–602.
148. Elemam A, Rahimian J, Mandell W. Infection with panresistant *Klebsiella pneumoniae*: a report of 2 cases and a brief review of the literature. *Clin Infect Dis.* 2009;49:271–4.
149. Endimiani A, Perez F, Bajaksouzian S, Windau AR, Good CE, Choudhary Y, et al. Evaluation of updated interpretative criteria for categorizing *Klebsiella pneumoniae* with reduced carbapenem susceptibility. *J Clin Microbiol.* 2010;48:4417–25.
150. Daikos GL, Markogiannakis A. Carbapenemase-producing *Klebsiella pneumoniae*: (when) might we still consider treating with carbapenems. *Clin Microbiol Infect.* 2011;17:1135–41.
151. Daikos GL, Panagiotakopoulou A, Tzelepi E, Loli A, Tzouvelelis LS, Miriagou V. Activity of imipenem against the VIM-1 metallo-beta-lactamase-producing *Klebsiella pneumoniae* in the murine thigh infection model. *Clin Microbiol Infect.* 2007;13:202–5.

152. Souli M, Konstantinidou E, Tzepe I, Tsaganos T, Pefanis A, Chryssouli Z, et al. Efficacy of carbapenems against a metallo- $\beta$ -lactamase-producing *Escherichia coli* clinical isolate in a rabbit intra-abdominal abscess model. *J Antimicrob Chemother.* 2011;66:611–7.
153. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. *J Clin Pharmacol.* 2003;43:1116–23.
154. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against *Klebsiella pneumoniae* producing the KPC carbapenemase versus that against *Pseudomonas aeruginosa* in an in vitro pharmacodynamic model. *Antimicrob Agents Chemother.* 2010;54:804–10.
155. Bulik CC, Nicolau DP. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2010;54:4112–5.
156. Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, LaBombard VJ, Nicolau DP, et al. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing *Klebsiella pneumoniae* isolates by various testing methods. *J Clin Microbiol.* 2010;48:2402–6.
157. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. Efficacy of humanized carbapenem exposures against New Delhi metallo- $\beta$ -lactamase (NDM-1)-producing *Enterobacteriaceae* in a murine infection model. *Antimicrob Agents Chemother.* 2013;57:3936–40.
158. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. Efficacy of humanized carbapenem and ceftazidime regimens against *Enterobacteriaceae* producing the OXA-48 carbapenemase in a murine infection model. *Antimicrob Agents Chemother.* 2014;58:1678–83.
159. Hagihara M, Crandon JL, Urban C, Nicolau DP. Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing *Klebsiella pneumoniae* with similar MICs. *J Antimicrob Chemother.* 2013;68:1616–8.
160. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2011;55:3002–4.
161. Wiskirchen DE, Crandon JL, Nicolau DP. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing *Klebsiella pneumoniae*. *Int J Antimicrob Agents.* 2013;41:582–5.
162. Giamarellou H, Galani L, Baziaka F, Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2013;57:2388–90.
163. Ceccarelli G, Falcone M, Giordano A, Mezzatesta ML, Caio C, Stefani S, et al. Successful ertapenem–doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2013;57:2900–1.
164. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, et al. Carbapenem-sparing by antibiotic regimens for infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* in intensive care unit. *Clin Infect Dis.* 2013;56:597–700.
165. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2013. Available from: <http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf>
166. Yahn H, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. *Clin Microbiol Infect.* 2012;18:18–29.
167. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2002;46:1946–52.
168. Rodríguez-Hernández M-J, Jiménez-Mejías M, Pichardo C, Cuberos L, García-Curiel A, Pachón J. Colistin efficacy in an experimental model of *Acinetobacter baumannii* endocarditis. *Clin Microbiol Infect.* 2004;10:581–4.
169. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. *Lancet Infect Dis.* 2006;6:589–601.
170. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case–control study. *Crit Care Med.* 2008;36:807–11.
171. Kontopidou F, Plachouras D, Papadomichelakis E, Koukos G, Galani I, Poulakou G, et al. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. *Clin Microbiol Infect.* 2011;17:E9–11.
172. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of methanesulphonate. *J Antimicrob Chemother.* 2004;53:837–40.
173. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontifakis K, Jansson B, et al. Application of a loading dose of colistin methanesulphonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. *Antimicrob Chemother.* 2012;56:4241–9.
174. Baronzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulphonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. *Antimicrob Agents Chemother.* 2011;55:3284–94.
175. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with gram-negative bacterial infections. *Antimicrob Agents Chemother.* 2009;53:3430–6.
176. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. *Clin Infect Dis.* 2013;56:398–404.
177. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. *J Infect.* 2011;62:187–90.
178. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. *Clin Infect Dis.* 2009;48:1724–8.
179. Dalfino L, Puntillo F, Mosca A, Minno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy. A preliminary study. *Clin Infect Dis.* 2012;54:1720–6.
180. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. *Int J Antimicrob Agents.* 2010;35:297–300.
181. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study. *Intensive Care Med.* 2007;33:1162–7.
182. Michalopoulos AS, Tsiodras S, Rellos A, Krentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multidrug-resistant Gram-negative bacteria: the renaissance of an old antibiotic. *Clin Microbiol Infect.* 2005;11:115–21.
183. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittell M, et al. Treatment of multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. *Clin Infect Dis.* 2003;36:1111–8.
184. Marchand S, Frat J-P, Petitpas F, Lemaître F, Gobin P, Robert R, et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. *J Antimicrob Chemother.* 2010;65:1836–7.
185. Karaiskos I, Plachouras D, Friberg LE, Parfamythiotou E, Papadomichelakis E, Karaiskos M, et al. Colistin methanesulphonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. *Antimicrob Agents Chemother.* 2013;57:668–71.
186. Markou N, Fousteri M, Markantonis SL, Zidianakis B, Hroni D, Boutzouka E, et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. *J Antimicrob Chemother.* 2012;67:2459–62.
187. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. *Clin Infect Dis.* 2008;46:1069–77.
188. Karageorgopoulos DE, Wang R, Yu XY, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. *J Antimicrob Chemother.* 2012;67:255–68.
189. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. *Int J Antimicrob Agents.* 2009;34:111–20.
190. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum  $\beta$ -lactamase producing, *Enterobacteriaceae* infections: a systematic review. *Lancet Infect Dis.* 2010;10:43–50.
191. Endimiani A, Petal G, Hujer KM, Swaminathan M, Perez F, Rice LB, et al. In vitro activity of fosfomycin against blaKPC-containing *Klebsiella pneumoniae* isolates, including those non-susceptible to tigecycline and/or colistin. *Antimicrob Agents Chemother.* 2010;54:526–9.
192. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) *Enterobacteriaceae* isolates to fosfomycin. *Int J Antimicrob Agents.* 2010;35:240–3.
193. Pena I, Pizarro JJ, Rodríguez-Avial C, Rodríguez-Avial I. Carbapenemase-producing *Enterobacteriaceae* in a tertiary hospital in Madrid, Spain: high percentage of colistin resistance among VIM-1-producing *Klebsiella pneumoniae* ST11 isolates. *Int J Antimicrob Agents.* 2014;43:460–4.
194. Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant *Klebsiella pneumoniae*, *Escherichia coli*, and *Pseudomonas aeruginosa* clinical isolates. *Eur J Clin Microbiol Infect Dis.* 2012;31:695–701.
195. Netik T, Leelaporn A, Leelarasmea B, Kiratisin P. In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible *Escherichia coli* and *Klebsiella pneumoniae*. *Int J Antimicrob Agents.* 2010;35:609–10.
196. Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing *Klebsiella pneumoniae* by in vitro time-kill experiments. *Antimicrob Agents Chemother.* 2014;58:1757–62.
197. Souli M, Galani I, Boukavalas S, Gourgoulis MG, Chryssouli Z, Kanellakopoulou K, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing *Klebsiella pneumoniae* and protection of resistance development. *Antimicrob Agents Chemother.* 2011;55:2395–7.

198. Michalopoulos A, Virtzilli S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomicin for the treatment of nosocomial infections caused by carbapenem-resistant *Klebsiella pneumoniae* in critically ill patients: a prospective evaluation. *Clin Microbiol Infect.* 2010;16:184–6.
199. Karageorgopoulos DE, Miriagou V, Tzouveleki LS, Spyridopoulou K, Daikos GL. Emergence of fosfomicin used as adjunct therapy in KPC-*Klebsiella pneumoniae* bacteraemia: report of three cases. *J Antimicrob Chemother.* 2012;67:2777–9.
200. Pontikis K, Karaïskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomicin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. *Int J Antimicrob Agents.* 2014;43:52–9.
201. Parker S, Lipman J, Kouletis D, Dimopoulos G, Roberts JA. What is the relevance of fosfomicin pharmacokinetics in the treatment of serious infections in critically ill patients. A systematic review. *Int J Antimicrob Agents.* 2013;42:289–93.
202. Vidal L, Gafter-vili Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother.* 2007;60:247–57.
203. Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. *J Antimicrob Chemother.* 2009;63:246–51.
204. Le J, McKee B, Srisupha-Olarn W, Burgess DS. In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing *Klebsiella pneumoniae*. *J Clin Med Res.* 2011;3:106–10.
205. Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, et al. Assessment of antimicrobial combinations for *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*. *J Infect Dis.* 2013;207:786–93.
206. Mentec H, Vallois JM, Bure A, Saleh-Mghir A, Jehl F, Carbon C. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by TEM-3-producing strain or its susceptible variant. *Antimicrob Agents Chemother.* 1992;36:1883–9.
207. Szabó D, Máthe a, Filetóth Z, Anderlik P, Rókusuz L, Rozgonyi F. In vitro and in vivo activities of amikacin, cefepime, amikacin plus ceftazidime, and imipenem against an SHV-5 extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* strain. *Antimicrob Agents Chemother.* 2001;45:1287–91.
208. Máthe A, Szabó D, Anderlik P, Rozgonyi F, Nagy K. The effect of amikacin and imipenem alone and in combination against an extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* strain. *Diagn Microbiol Infect Dis.* 2007;58:105–10.
209. Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V, Papahatzaki H, et al. Outbreak of infections due to KPC-2-producing *Klebsiella pneumoniae* in a hospital in Crete (Greece). *J Infect.* 2009;58:213–9.
210. Benenson S, Navon-Venezia S, Carmeli Y, Adler A, Strahilevitz J, Moses AE, et al. Carbapenem-resistant *Klebsiella pneumoniae* endocarditis in a young adult successful treatment with gentamicin and colistin. *Int J Infect Dis.* 2009;13:e295–8.
211. Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne WM Jr, Chiche DJ. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing *Enterobacteriaceae* in a retrospective cohort. *Clin Ther.* 2012;34:1314–23.
212. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* bacteremia. *J Hosp Infect.* 2002;52:99–106.
213. Endimiani A, Luzzaro F, Perilli M, Lombardi G, Coli A, Tamborini A, et al. Bacteremia due to *Klebsiella pneumoniae* isolates producing the TEM-52 extended-spectrum  $\beta$ -lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. *Clin Infect Dis.* 2004;38:243–51.
214. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Císnal M, Duarte R, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing *Escherichia coli* (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. *J Antimicrob Chemother.* 2010;65:333–41.
215. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. *Crit Care.* 2010;14:R53.
216. Layeux B, Taccone FS, Fagnoul D, Vincent JL, Jacobs F. Amikacin monotherapy for sepsis caused by panresistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2010;54:4939–41.
217. Rodríguez-Baño J, Cisneros JM, Gudiol C, Martínez JA. Treatment of infections caused by carbapenemase-producing *Enterobacteriaceae*. *Enferm Infecc Microbiol Clin.* 2014;32 Suppl 4:49–55.
218. Panagiotakopoulos A, Daikos GL. Comparative in vitro killing of carbapenems and aztreonam against *Klebsiella pneumoniae* producing VIM-1 metallo- $\beta$ -lactamase. *Int J Antimicrob Agents.* 2007;29:356–65.
219. Souli M, Konstantinidou E, Tzetsi I, Tsaganos T, Pefanis A, Chrysouli Z, et al. Efficacy of carbapenems against a metallo- $\beta$ -lactamase-producing *Escherichia coli* clinical isolate in a rabbit intra-abdominal abscess model. *J Antimicrob Chemother.* 2011;66:611–7.
220. Mimoz O, Grégoire N, Poirol L, Maillat M, Couet W, Nordmann P. Broad-spectrum  $\beta$ -lactam antibiotics for treating carbapenemase OXA-48. In mice due to *Klebsiella pneumoniae* producing the carbapenemase OXA-48. *Antimicrob Agents Chemother.* 2012;56:2759–60.
221. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. *Int J Infect Dis.* 2005;9:251–61.
222. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. *Antimicrob Agents Chemother.* 2005;49:4658–66.
223. Matthews P, Alpert M, Rahav G, Rill D, Zito E, Gardiner D, et al. A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections. *BMC Infect Dis.* 2012;12:297.
224. Tanaseanu C, Milutinovic S, Calstru PI, Strausz J, Zolubas M, Chernyak V, et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. *BMC Pulm Med.* 2009;9:44.
225. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. *Diagn Microbiol Infect Dis.* 2009;63:52–61.
226. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyubliuk O, Glumcher F, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. *Diagn Microbiol Infect Dis.* 2010;68:140–51.
227. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. *Antimicrob Agents Chemother.* 2013;57:1756–62.
228. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. *BMC Infect Dis.* 2005;5:88.
229. Fomin P, Beuran M, Gradauskas A, Barauskas G, Datsenko A, Dartois N, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. *Int J Surg.* 2005;3:35–47.
230. Chen Z, Wu J, Zhang Y, Wei J, Leng X, Bi J, et al. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. *BMC Infect Dis.* 2010;10:217.
231. Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T. A multicenter, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. *Clin Microbiol Infect.* 2010;16:1274–81.
232. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. *Antimicrob Agents Chemother.* 2011;55:1162–72.
233. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. *Lancet Infect Dis.* 2011;11:834–44.
234. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. *J Antimicrob Chemother.* 2011;66:1963–71.
235. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. *Clin Infect Dis.* 2012;54:1699–709.
236. Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse *Escherichia coli* and *Klebsiella pneumoniae* isolates. *Antimicrob Agents Chemother.* 2009;53:2756–61.
237. Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. *Antimicrob Agents Chemother.* 2008;52:204–10.
238. Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, et al. Pharmacokinetic and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. *Antimicrob Agents Chemother.* 2012;56:1065–72.
239. Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, et al. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-*Enterobacteriaceae* susceptibility breakpoints. *Diagn Microbiol Infect Dis.* 2009;63:38–42.
240. García-Rodríguez JA, Grupo de Estudio de Sensibilidad Antibiótica. Multicenter study of in vitro activity of tigecycline in clinical isolates from 30 centers in Spain. *Rev Esp Quimioter.* 2009;22:76–82.
241. Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). *Diagn Microbiol Infect Dis.* 2013;76:217–21.
242. Hope R, Warner M, Potz NA, Fagan EJ, James D, Livermore DM. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing *Enterobacteriaceae* from south-east England. *J Antimicrob Chemother.* 2006;58:1312–4.
243. Froment Gomis P, Jean-Pierre H, Rousseau-Didelot MN, Compan B, Michon AL, Godreuil S. Tigecycline: CMI 50/90 towards 1766 Gram-negative bacilli (3rd generation cephalosporins resistant *Enterobacteriaceae*), *Acinetobacter baumannii* and *Bacteroides fragilis* group, University Hospital – Montpellier, 2008–2011. *Pathol Biol (Paris).* 2013;61:282–5.
244. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including *Enterobacter* species, *Acinetobacter baumannii* and *Klebsiella pneumoniae*. *J Antimicrob Chemother.* 2008;62 Suppl. 1:i29–40.

245. Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. *J Infect.* 2009;58:273–84.
246. Curcio D, Fernández F, Cané A, Barcelona L, Stamboulia D. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. *Braz J Infect Dis.* 2008;12:198–201.
247. Eckmann C, Heizmann WR, Leitner E, von Eiff C, Bodmann KF. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice. *Chemotherapy.* 2011;57:275–84.
248. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. Clinical outcomes of patients with *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* after treatment with imipenem or meropenem. *Diagn Microbiol Infect Dis.* 2009;64:233–5.
249. Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E, Vitti D, et al. Clonal spread of KPC-2 carbapenemase-producing *Klebsiella pneumoniae* strains in Greece. *J Antimicrob Chemother.* 2009;64:348–52.
250. Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of *Acinetobacter baumannii* and/or carbapenem-resistant *Enterobacteriaceae* infections. *Am J Infect Control.* 2012;40:983–7.
251. Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, et al. Carbapenem-resistant *Klebsiella pneumoniae* bacteremia: factors correlated with clinical and microbiologic outcomes. *Diagn Microbiol Infect Dis.* 2010;67:180–4.
252. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, et al. Treatment and outcomes in carbapenem-resistant *Klebsiella pneumoniae* bloodstream infections. *Diagn Microbiol Infect Dis.* 2011;69:357–62.
253. Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant *Klebsiella pneumoniae* from urine. *Antimicrob Agents Chemother.* 2011;55:5893–9.
254. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. High rate of colistin resistance among patients with carbapenem-resistant *Klebsiella pneumoniae* infection accounts for an excess of mortality. *Clin Microbiol Infect.* 2013;19:E23–30.
255. De Pascale G, Montini L, Pennisi MA, Bernini V, Maviglia R, Bello G, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. *Crit Care.* 2014;18:R90.
256. Balandin Moreno B, Fernandez Simon I, Pintado García V, Sanchez Romero I, Isidoro Fernández B, Romera Ortega MA, et al. Tigecycline therapy for infections due to carbapenemase-producing *Klebsiella pneumoniae* in critically ill patients. *Scand J Infect Dis.* 2014;46:175–80.